Endovascular Stent-Electrode Arrays: A Minimally Invasive Revolution in Neural Recording and Brain-Computer Interfaces

Abstract

Endovascular stent-electrode arrays represent a paradigm shift in neural interface technology, offering a minimally invasive alternative to traditional brain-computer interfaces (BCIs) that require open brain surgery. This article systematically reviews the foundational principles, methodological advancements, and clinical applications of this emerging technology. We explore how electrodes delivered via the cerebral venous system enable stable, long-term neural recording with fidelity comparable to subdural arrays, as demonstrated in preclinical and early clinical studies. The content addresses key optimization challenges, including signal processing and electrode biocompatibility, and provides a comparative analysis against existing neural recording modalities. For researchers and drug development professionals, this synthesis offers critical insights into the current state, technical hurdles, and future therapeutic potential of endovascular BCIs for treating neurological disorders and advancing neuroprosthetic applications.

The Principles and Evolution of Endovascular Neural Interfaces

An endovascular brain-computer interface (BCI) is a medical device that enables direct communication between the brain and external digital devices, such as computers, by translating neural activity into commands [1]. This technology represents a paradigm shift in neural interfacing, as it utilizes the body's natural venous system as a pathway to place recording electrodes adjacent to the motor cortex, avoiding the need for open-brain surgery [2] [3]. Traditional invasive BCI approaches, such as electrocorticography (ECoG) and stereoelectroencephalography (SEEG), require craniotomy and direct placement of electrodes on or within brain tissue, carrying risks of hematoma, infection, and blood-brain barrier disruption [3]. In contrast, endovascular BCIs offer a minimally invasive alternative by deploying stent-electrode arrays via the jugular vein using catheter-based neurointerventional techniques similar to those used in thrombectomy or vascular stenting [4] [5]. The primary clinical aim of this technology is to restore functional autonomy to people with severe paralysis by enabling them to control digital devices through thought alone [1].

Technical Foundations and Key Advantages

The core component of an endovascular BCI is the stent-electrode array (commercially known as Stentrode), a conformable nitinol stent structure integrated with multiple platinum recording electrodes [4] [6]. Typically featuring 16 electrodes, the device is designed for permanent implantation in the superior sagittal sinus, a major venous sinus situated adjacent to the primary motor cortex [4] [7]. This strategic placement allows the electrodes to record electrocorticography (ECoG) signals from the region of the brain responsible for movement intention.

The endovascular approach offers several distinct advantages over traditional invasive BCIs. By residing within a blood vessel rather than in direct contact with brain tissue, the device avoids the foreign body response and glial scarring that often lead to signal degradation in chronically implanted cortical electrodes [3]. Furthermore, the implantation procedure is substantially less invasive than craniotomy, potentially reducing recovery time and surgical risks such as infection [2] [3]. The signal quality obtained from this endovascular location has been shown to rival that of subdural electrode arrays, with sufficient fidelity to decode movement intention and control external devices [2] [7].

Table: Key Advantages of Endovascular BCIs Over Traditional Invasive Approaches

Feature	Endovascular BCI	Traditional Invasive BCI
Surgical Access	Minimally invasive via jugular vein	Requires craniotomy or craniectomy
Surgical Risk Profile	Lower risk of brain tissue damage, infection	Risks of hematoma, infection, BBB disruption
Signal Stability	Potentially more stable long-term due to reduced gliosis	Signal degradation possible due to glial scarring
Targeting Capability	Access to motor cortex via superior sagittal sinus	Direct cortical access but limited coverage area
Clinical Translation	Favorable safety profile could promote wider adoption	Invasiveness may limit application scale

Clinical Application and Performance Data

Endovascular BCIs have demonstrated promising results in clinical applications, particularly for individuals with severe bilateral upper-limb paralysis resulting from conditions such as amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis [4]. Clinical studies have shown that implanted patients can successfully use the system for digital communication and instrumental activities of daily living, including texting, emailing, online shopping, and communicating care needs [4] [1].

The SWITCH first-in-human study (NCT03834857) and the COMMAND early feasibility study (NCT05035823) have provided the most comprehensive clinical data to date [4] [5]. These trials evaluated the safety and efficacy of the Stentrode device in patients with severe paralysis, with follow-up periods extending to 12 months.

Table: Clinical Outcomes from Endovascular BCI Trials

Study Parameter	SWITCH Study Results	COMMAND Study Results
Participants	4 patients with severe bilateral upper-limb paralysis	6 patients with severe chronic bilateral upper-limb paralysis
Primary Safety Endpoint	No device-related serious adverse events	No device-related serious adverse events
Secondary Safety	No vessel occlusion or device migration	No serious adverse events related to brain or vasculature
Signal Characteristics	Mean signal bandwidth: 233 (16) Hz, stable over 12 months	Stable signal performance over 12 months
Functional Control	All patients successfully controlled a computer with BCI	All patients generated digital motor outputs for task control
Deployment Success	N/R	100% accurate deployment, median time 20 minutes

Beyond these quantitative metrics, qualitative functional outcomes have been significant. Participants have achieved hands-free digital device control using only their thought-derived intentions, translating to meaningful improvements in autonomy and quality of life [4] [5]. The system has been used with various software platforms, including recently demonstrated compatibility with Amazon Alexa virtual assistant technology [5].

Experimental Protocols and Methodologies

Device Implantation Protocol

The implantation of an endovascular BCI follows a standardized protocol that begins with patient selection based on specific inclusion criteria: adults with severe bilateral upper-limb paralysis who retain motor cortex activity as confirmed by functional MRI, and who have venous anatomy suitable for device placement [4]. Key exclusion criteria include contraindications to antiplatelet therapy and insufficient motor cortex activation.

The preoperative preparation involves high-resolution imaging to map the neurovascular anatomy. Patients undergo magnetic resonance imaging (MRI) to assess the suitability of the venous pathway and motor cortex location, complemented by computed tomography (CT) venography for baseline vascular assessment [4]. Patients initiate dual antiplatelet therapy two weeks before implantation to reduce thrombosis risk [4].

The surgical procedure is performed under general anesthesia in an angiographic operating room. Using techniques derived from neurointerventional practice, access is gained via percutaneous puncture of the internal jugular vein. A guide catheter is navigated to the target location in the superior sagittal sinus adjacent to the precentral gyrus, guided by 3-dimensional digital subtraction angiography coregistered with preoperative structural MRI [4]. The stent-electrode array is then advanced through the guide catheter and deployed under fluoroscopic guidance. The lead is tunneled subcutaneously to an implantable receiver transmitter unit (IRTU) placed in an infraclavicular pocket [4].

Neural Signal Processing Protocol

Following implantation, a systematic approach to signal acquisition and processing enables the translation of neural activity into device commands. The recording device captures neural signals from the motor cortex, which are transmitted wirelessly to an external controller that translates them into commands for computer control [4].

The signal decoding protocol involves several stages. First, the system is calibrated by recording neural activity during periods of rest and attempted limb movement. The power in specific frequency bands, particularly targeting β activity (13-30 Hz), is extracted as features [4]. A machine learning classifier (typically a support vector machine or threshold classifier) is then trained to distinguish between these states, creating a mapping between neural patterns and intended commands [4].

For continuous operation, patients use the calibrated system to control digital interfaces. The neural decoder generates switch outputs that emulate computer mouse functions, often used in combination with eye-tracking technology for cursor navigation [4]. Performance is quantified through metrics such as characters per minute in typing tasks, selection accuracy, and response accuracy [4].

Research Reagents and Materials

The development and implementation of endovascular BCIs requires specialized materials and reagents optimized for biocompatibility, electrical performance, and long-term stability in the vascular environment.

Table: Essential Research Reagents and Materials for Endovascular BCI Studies

Material/Reagent	Specification/Composition	Primary Function
Stent-Electrode Array	Nitinol stent with integrated platinum electrodes (0.3mm² surface area, 3mm spacing)	Neural signal recording from within blood vessel
Implantable Receiver Transmitter Unit (IRTU)	Hermetically sealed titanium casing with electronics	Wireless transmission of neural data to external device
Anti-platelet Therapy	Dual antiplatelet regimen (e.g., aspirin + clopidogrel)	Prevention of thrombotic events post-implantation
Angiographic Catheter System	2-mm guide catheter, microcatheters	Endovascular access and device deployment
Platinum Black Coating	Sputter-coated high-purity platinum	Enhanced charge injection capacity for stimulation
Zirconium Oxide Insulation	250nm thick layers	Electrical isolation of electrode conducting tracks

Recent research has focused on material enhancements to improve device performance. Platinum black coatings have shown particular promise, demonstrating substantially increased electroactive surface area compared to uncoated platinum, resulting in improved charge injection capacity while maintaining electrochemical stability during continuous stimulation [6]. These advancements are critical for the development of future bidirectional endovascular interfaces capable of both recording and stimulating neural activity.

Signaling Pathways and Neural Decoding

The fundamental physiological principle underlying endovascular BCI function is the detection and interpretation of motor-related neural signals associated with movement intention. The primary motor cortex generates characteristic electrical patterns when a person attempts to execute movements, even when those movements cannot be physically performed due to paralysis [4].

The key signal features used for decoding movement intention include modulations in specific frequency bands of the local field potential. Particularly important are changes in the β-band (13-30 Hz) and high-frequency bands (30-200 Hz), which show characteristic power decreases during movement execution or attempt [4] [7]. These frequency-specific changes are stable over time, enabling reliable decoding of user intent throughout long-term implantation [7].

The neural decoding process translates these raw signals into actionable commands through a multi-stage pipeline. After signal acquisition, preprocessing removes noise and artifacts. Feature extraction then identifies relevant signal characteristics, primarily focusing on spectral power in specific frequency bands. Finally, a classification algorithm maps these features to intended user commands, creating a real-time control interface [4].

Future Directions and Research Challenges

While endovascular BCIs have demonstrated promising safety and feasibility profiles, several research challenges must be addressed to advance the technology. Key areas include optimizing signal processing algorithms, enhancing electrode biocompatibility and long-term stability, and refining endovascular procedures for broader clinical applications [2] [8]. The risk of thrombosis, though minimal in current studies, remains a consideration that necessitates continued material innovation [2].

Future development is also focusing on expanding functional capabilities, including the implementation of bidirectional communication that would enable both recording from and stimulating the brain [6]. Recent work with platinum black modified electrodes has shown substantial improvements in charge injection capacity, potentially enabling safe stimulation of neural tissue from an endovascular location [6]. Additionally, efforts are underway to increase the number of recording channels and improve spatial resolution, which would enhance the granularity of control available to users.

The favorable safety profile of endovascular BCIs compared to fully invasive approaches could promote wider and more rapid translation to people with paralysis [4]. As the technology evolves, it holds the potential to provide continuous autonomy through digital access with minimal caregiver assistance, fundamentally transforming the quality of life for individuals with severe motor impairments.

The development of brain-machine interfaces (BMIs) and advanced neurostimulation therapies has historically been constrained by the risks and limitations of open brain surgery required for electrode implantation. Traditional intracranial electrodes, while providing high-fidelity signals, necessitate direct penetration of neural tissue, which can lead to inflammatory responses, glial scarring, and disruption of normal brain function [9] [10]. This document outlines the anatomical and physiological rationale for using the cerebral vascular system as a natural conduit to access deep brain structures, enabling minimally invasive neural recording and stimulation through endovascular stent-electrode arrays.

The fundamental premise of this approach is that blood vessels form an intricate, pervasive network throughout the brain, reaching virtually all regions of interest for neural interfacing. By deploying recording and stimulation devices within these vascular channels, researchers can position electrodes in close proximity to neural tissue without requiring direct parenchymal penetration [9] [11]. This endovascular strategy significantly reduces surgical morbidity, minimizes tissue damage, and provides a stable platform for chronic neural recording.

Anatomical Foundations

The Cerebrovasculature as a Biological Scaffold

The cerebral venous system, particularly the superior sagittal sinus (SSS) and associated cortical veins, provides an optimal anatomical foundation for endovascular neural interfaces. These vascular structures course immediately adjacent to critical brain regions, separated from neural tissue only by a thin vascular wall and the pia mater [11]. The superior sagittal sinus runs along the midline of the brain and overlies primary motor and sensory cortices, making it ideally situated for recording neural signals related to movement and sensation.

The confluence of sinuses, where the superior sagittal sinus, straight sinus, and transverse sinuses meet, provides vascular access to occipital brain regions involved in visual processing [10]. Anatomical studies in both ovine and human models have demonstrated the structural similarity of these venous systems, supporting the translational potential of endovascular approaches from animal models to human applications [11] [10].

Table: Key Vascular Structures for Endovascular Neural Access

Vascular Structure	Anatomical Location	Adjacent Brain Regions	Accessibility
Superior Sagittal Sinus (SSS)	Midline, along falx cerebri	Primary motor cortex, Sensory cortex	High (via transvenous access)
Confluence of Sinuses	Occipital pole	Visual cortex	Moderate (requires navigation)
Transverse Sinus (TrS)	Lateral, along tentorium cerebelli	Temporal lobe, Occipital lobe	Moderate
Sigmoid Sinus (SiS)	Inferolateral, connecting to jugular	Cerebellum, Brainstem	High (direct jugular access)

Comparative Vascular Anatomy

Research utilizing sheep models has been particularly valuable due to the remarkable similarity between ovine and human intracranial venous anatomy [10]. Digital subtraction angiography (DSA) studies have quantified key venous dimensions, confirming the feasibility of deploying endovascular devices in these models with direct relevance to human applications. The transverse sinus in sheep measures approximately 2.30 mm in diameter, while the sigmoid sinus is significantly larger at ~5.79 mm, readily accommodating microcatheter delivery systems [10].

Endovascular Neural Interface Platforms

Stentrode: The Stent-Electrode Array

The Stentrode represents a pioneering approach in which a self-expanding nitinol stent serves as both a vascular scaffold and an electrode platform. Once deployed within a cortical vein or venous sinus, the stent maintains patency while electrode contacts appose the vessel wall in close proximity to adjacent neural tissue [11]. Chronic studies in sheep models have demonstrated the ability to record brain activity for up to 190 days with signal quality comparable to traditional epidural surface arrays [11].

The Stentrode provides access to cortical surface signals, capturing local field potentials (LFPs) and broader electrocorticography (ECoG)-type signals suitable for decoding motor intentions and other population-level neural dynamics [11].

uFINE-I: Ultraflexible Intravascular Neural Electrodes

For recordings at higher spatial resolution, including single-unit activity, the ultraflexible implantable neural electrode (uFINE-I) has been developed. This device features a linear array of 30 micro-scale electrode sites (30μm diameter, 40μm spacing) distributed along a polyimide substrate that is only 5μm thick and 120μm wide [10]. The extreme flexibility of this platform enables navigation through tortuous venous structures and penetration through vessel walls into adjacent neural tissue while minimizing vascular injury.

The uFINE-I represents a significant advancement by enabling intravascular access to single-neuron resolution recordings, previously only achievable with direct parenchymal penetration [10]. This capability was demonstrated in the sheep occipital lobe, where the device successfully recorded both LFPs and multi-channel single-unit spiking activity under spontaneous and visually evoked conditions.

Table: Comparative Performance of Endovascular Neural Interfaces

Parameter	Stentrode [11]	uFINE-I [10]	Traditional ECoG [9]
Recording Type	Vascular ECoG	Single-unit & LFP	Cortical surface ECoG
Spatial Resolution	0.5-5 mm	Single neuron (~1.2mm span)	0.5-5 mm
Invasiveness	Minimally invasive (venous)	Minimally invasive (venous penetration)	Highly invasive (craniotomy)
Chronic Stability	Up to 190 days demonstrated	Limited long-term data	Variable (weeks to months)
Target Brain Regions	Cortical surfaces adjacent to sinuses	Deep cortical layers via penetration	Cortical surfaces
Signal Bandwidth	Comparable to epidural ECoG	Local field potentials & single-unit	Full bandwidth ECoG

Experimental Protocols

Pre-implantation Planning and Anatomical Mapping

Objective: To identify suitable vascular access routes and validate device placement for target neural structures.

Materials:

• Digital Subtraction Angiography (DSA) system
• 3D anatomical modeling software (e.g., 3D Slicer)
• Microcatheters for exploratory angiography
• Contrast agents

Methodology:

• Perform diagnostic cerebral venography via jugular or femoral access
• Administer contrast agent to visualize intracranial venous architecture
• Acquire multi-planar DSA images to create 3D venous roadmaps
• Measure vessel diameters, tortuosity, and identify anatomical landmarks
• Correlate vascular anatomy with cortical regions using co-registered MRI
• Identify optimal deployment sites based on target neural structures and vascular accessibility

Validation: Compare preoperative plans with postoperative imaging to confirm accurate device placement relative to target brain regions [11] [10].

Stertrode Implantation Protocol

Objective: To safely deploy a stent-electrode array within the superior sagittal sinus or cortical veins overlying target neural regions.

Materials:

• Stentrode delivery system (catheter-based)
• Fluoroscopic guidance system
• Heparinized saline flush
• Vascular access kit

Methodology:

• Establish venous access (typically via femoral or jugular approach)
• Navigate delivery catheter to target deployment site under fluoroscopic guidance
• Position stent-electrode array precisely over target cortical region
• Deploy self-expanding stent, ensuring wall apposition without vessel obstruction
• Confirm position with contrast angiography
• Secure externalized leads to access site
• Initiate antiplatelet therapy to maintain vessel patency

Quality Control: Verify electrode functionality intraoperatively and confirm venous patency post-procedure [11].

uFINE-I Implantation and Vessel Penetration Protocol

Objective: To deliver ultraflexible electrodes through the venous wall into adjacent brain tissue for single-unit recording.

Materials:

• Custom microcatheter (1.7F/0.57mm outer diameter)
• Puncture microneedle and guiding microwire
• uFINE-I electrode array
• Balloon catheter for stabilization (optional)

Methodology:

• Navigate delivery system to target vein (e.g., confluence of sinuses)
• Position microcatheter tip against vessel wall at desired penetration site
• Deploy microneedle to create minimal wall perforation
• Advance guiding microwire through perforation into brain tissue
• Use microwire to guide uFINE-I electrode array into parenchyma
• Retract delivery system while securing electrode position
• Confirm placement with postoperative imaging (CT/MRI)

Validation: Histological analysis post-sacrifice to verify minimal tissue damage and track electrode placement [10].

Neural Signal Acquisition and Processing Protocol

Objective: To record and analyze neural signals acquired via endovascular approaches.

Materials:

• High-impedance electrophysiology system
• Reference and ground electrodes
• Signal processing software (MATLAB, Python)
• Wireless transmitter (for chronic applications)

Methodology:

• Connect to electrode contacts via externalized or wireless connection
• Acquire raw neural signals with appropriate sampling rate (>30kHz for spikes, ~2kHz for LFP)
• Apply bandpass filtering (300-5000Hz for spiking activity, 0.5-300Hz for LFP)
• Perform spike sorting using principal component analysis and clustering algorithms
• Decode behavioral correlates using support vector machines or neural networks
• For chronic recordings, monitor signal stability over time

Analysis: Compare signal characteristics with traditional recording modalities to validate recording quality [11] [10].

Visualization of Endovascular Access Workflows

The Scientist's Toolkit: Essential Research Reagents and Materials

Table: Critical Components for Endovascular Neural Interface Research

Component	Specification	Function/Rationale
Stentrode Array	Nitinol stent with platinum-iridium electrodes [11]	Self-expanding vascular scaffold that positions recording electrodes against vessel wall
uFINE-I Electrode	5μm thick polyimide with 30 IrOx/PEDOT:PSS sites (30μm) [10]	Ultraflexible platform for vessel wall penetration and single-unit recording
Delivery Microcatheter	1.7F (0.57mm) outer diameter, ~400mm length [10]	Navigates tortuous venous anatomy to reach target implantation sites
Guiding Microwire	<100μm diameter, torqueable [10]	Guides electrode through vessel wall penetration into brain tissue
Digital Subtraction Angiography	High-resolution fluoroscopic imaging	Provides real-time visualization of vascular anatomy and device deployment
Anti-platelet Regimen	Clopidogrel/ASA therapy [11]	Maintains vessel patency and prevents thrombus formation on implanted devices
Signal Acquisition System	High-impedance amplifier (>1GΩ) with wireless capability [11]	Records neural signals while minimizing noise and artifact in chronic settings

The cerebral vasculature provides a sophisticated biological scaffold for accessing neural circuits with minimal tissue disruption. Endovascular approaches represent a paradigm shift in neural interface technology, potentially enabling widespread clinical application of BMIs for conditions such as paralysis, epilepsy, and movement disorders. As these technologies evolve, they promise to bridge the gap between the high performance of invasive brain interfaces and the safety profile of non-invasive systems, opening new frontiers in both fundamental neuroscience and clinical neurology.

Endovascular stent-electrode arrays represent a paradigm shift in neural interfacing, offering a minimally invasive alternative to traditional brain-computer interfaces (BCIs) that require open-brain surgery. These devices are implanted via the vascular system, navigating through blood vessels to position recording electrodes adjacent to neural tissue without penetrating the brain parenchyma. This approach significantly reduces surgical morbidity while maintaining high-fidelity signal acquisition, bridging the critical gap between non-invasive techniques with poor spatial resolution and highly invasive methods with associated health risks [9]. The historical progression from early endovascular EEG concepts to modern Stentrode arrays demonstrates remarkable innovation in neurotechnology, driven by advances in materials science, endovascular procedures, and neural signal processing. This evolution has transformed what was once a theoretical concept into a viable clinical tool for treating neurological disorders and restoring function in patients with paralysis, framing a new chapter in minimally invasive neuromodulation and neural recording research [12].

Historical Development of Endovascular Neural Recording

Early Pioneering Work (1970s-1990s)

The foundation for endovascular neural interfaces was established in the early 1970s when researchers first demonstrated the feasibility of recording brain activity from within blood vessels. In 1973, Penn and colleagues conducted seminal experiments using a stainless-steel wire with a platinum cobalt magnet as an electroencephalogram (EEG) electrode placed in the carotid artery of baboons [12]. This early endovascular approach successfully detected higher amplitude signals compared to scalp EEG, as the intervening skull and dural tissue no longer dampened the electrical activity [12]. Throughout the 1990s, researchers advanced this concept in human studies, utilizing Seeker Lite-10 guidewires (0.31 mm in diameter with platinum tips) positioned in middle and anterior cerebral artery segments to improve epileptic foci detection [12]. These early experiments confirmed that endovascular electrodes could detect simultaneous spike discharges comparable to subdurally recorded signals, validating the fundamental principle that usable neural signals could be acquired through the vascular wall [13].

Technical Refinements and Challenges

Despite promising results, these early endovascular recording approaches faced significant limitations that restricted their clinical utility. Brief recording periods, particularly in arterial systems where prolonged catheterization posed safety concerns, limited data collection [12]. Researchers also struggled with signal artifacts from cardiac pulsation, patient movement, and adjacent electrical activity, complicating signal interpretation [12]. Spatial resolution remained constrained by single-electrode designs and anatomical limitations of accessible vasculature. To address the challenge of prolonged recording, researchers explored the venous system, which offered a safer profile for extended catheterization. Successful transvenous recordings were achieved for periods of up to 75 hours, though patient movement continued to generate problematic artifacts [12]. Signal origin ambiguity persisted despite techniques like bilateral hemisphere recording to subtract baseline artifact [13]. These collective challenges initially prevented widespread adoption of endovascular electrical recording, though they established critical design requirements for future generations of devices.

The Modern Stentrode Array

Device Architecture and Technical Specifications

The Stentrode system, developed by Synchron, represents the most advanced embodiment of the endovascular neural interface concept, addressing previous limitations through integrated electrode array design and chronic implantation capability. The device architecture consists of three primary components: a self-expanding nitinol stent scaffold that serves as the mechanical backbone; a thin-film electrode array embedded along the stent's luminal surface for neural signal acquisition; and a subcutaneous telemetry unit that digitizes, powers, and wirelessly transmits neural data to external processing hardware [14]. The nitinol stent leverages the alloy's superelastic and shape memory properties, enabling significant compressive deformation during catheter-based deployment and subsequent recovery of its original geometry within the target vessel [14]. The stent dimensions (approximately 40 mm in length and 8 mm in diameter) are optimized for implantation in the superior sagittal sinus (SSS) overlying the motor cortex [14].

The electrode array incorporates sixteen platinum-iridium electrodes coated with iridium oxide to enhance charge injection capacity and reduce electrode polarization [14]. These electrodes are lithographically patterned onto a polyimide film substrate using standard MEMS thin-film processes, with gold or platinum traces insulated by biocompatible dielectrics such as parylene-C to prevent electrical crosstalk [14]. The completed electrode array is wrapped around the interior curvature of the stent and adhesively bonded, ensuring circumferential distribution of electrode contact sites maintained in close apposition to the venous endothelium following deployment [14]. Following implantation, the device undergoes natural endothelialization where stent struts and electrode surfaces become enveloped by migrating endothelial cells within approximately four weeks, stabilizing the electrode-vessel interface without inducing thrombus formation or intimal hyperplasia [14].

Implantation Procedure and Signal Processing

The Stentrode implantation procedure leverages established endovascular techniques similar to those used for thrombectomy in ischemic stroke patients [11]. The device is delivered via catheter angiography through the internal jugular vein and navigated to the superior sagittal sinus under fluoroscopic guidance [14]. Positioned over the motor cortex, the self-expanding stent is deployed, apposing the electrode array against the venous wall [11]. The connecting lead is then tunneled subcutaneously to an implantable receiver-transmitter unit (IRTU) housed in a subclavicular pocket [14]. The IRTU performs critical functions including low-noise amplification, analog-to-digital conversion at sampling rates ≥1 kHz per channel to capture high-gamma ECoG activity, and wireless data transmission via Bluetooth Low Energy protocols to an external telemetry unit [14]. Power is delivered transcutaneously via inductive coupling, eliminating the need for percutaneous connectors and reducing infection risk [14].

Performance Comparison with Traditional Neural Interfaces

Quantitative Performance Metrics

The transition from early endovascular approaches to modern Stentrode technology has resulted in substantial improvements in recording capabilities, safety profiles, and clinical applicability. Table 1 provides a comprehensive comparison of key performance metrics across different neural interface modalities, illustrating the strategic position of endovascular Stentrode arrays in the trade space between invasiveness and signal fidelity.

Table 1: Performance Comparison of Neural Interface Technologies

Interface Type	Spatial Resolution	Signal Bandwidth	Invasiveness	Primary Clinical Applications	Key Limitations
Scalp EEG	1-3 cm [9]	0-100 Hz [9]	Non-invasive	Epilepsy monitoring, brain state interpretation [9]	Low spatial resolution, signal attenuation by skull [9]
ECoG (Subdural)	0.5-5 mm [9]	0-200 Hz [9]	High (requires craniotomy)	Epilepsy focus localization, cortical mapping [9]	Surgical morbidity, infection risk [2]
Intracortical Microelectrodes	200 μm (single units) [9]	100 Hz-10 kHz [15]	High (penetrating brain tissue)	Fundamental neuroscience, high-fidelity BCIs [16]	Tissue damage, inflammatory response, signal stability [16]
Early Endovascular EEG	~1 cm [12]	0-70 Hz [12]	Minimally invasive	Epileptic foci detection [12]	Limited spatial resolution, brief recording periods, artifact vulnerability [12]
Modern Stentrode	1-2.4 mm [9]	0-200 Hz (comparable to ECoG) [11] [12]	Minimally invasive	Paralysis (ALS, spinal cord injury), motor decoding [2] [14]	Constrained by venous anatomy, lower resolution than intracortical arrays [2]

Safety and Biocompatibility Profile

The Stentrode system demonstrates a favorable safety profile compared to traditional invasive neural interfaces. Preclinical studies in ovine models, which have cerebral venous anatomy comparable to humans, demonstrated maintained venous patency for up to 190 days post-implantation with complete endothelialization of the device [11] [14]. Histological analyses revealed preservation of endothelial integrity without significant thrombus formation or intimal hyperplasia [14]. To mitigate thromboembolic risk, patients receive dual antiplatelet therapy (aspirin and clopidogrel) for the first 90 days post-implantation, followed by aspirin monotherapy [14]. Clinical studies reported minimal vascular complications across six ALS patients, supporting the device's safety for chronic implantation in severely paralyzed patients [2]. The reduced infection risk compared to subdural grids, combined with the avoidance of brain penetration, positions the Stentrode as a compelling option for patients who may not be candidates for more invasive procedures [12].

Experimental Protocols and Methodologies

Preclinical Validation Protocol

The development and validation of endovascular stent-electrode arrays have followed rigorous experimental pathways encompassing both preclinical and clinical studies. Table 2 outlines the key methodological framework for preclinical Stentrode validation, synthesizing approaches from multiple research initiatives.

Table 2: Preclinical Validation Protocol for Endovascular Stent-Electrode Arrays

Experimental Component	Methodological Approach	Key Outcome Measures
Animal Model	Ovine model (chronic implantation) [11] [14]	Venous patency, endothelialization, signal stability over 190 days [11]
Device Implantation	Catheter angiography via jugular vein to superior sagittal sinus [11] [14]	Deployment accuracy, vessel wall apposition, acute complication rate [11]
Neural Recording	Comparison with simultaneous subdural and epidural arrays [11] [12]	Signal-to-noise ratio, bandwidth, spectral content [11]
Signal Processing	Custom algorithms for motor decoding [14]	Movement classification accuracy, information transfer rate [14]
Histological Analysis	Micro-CT and histological staining post-explantation [14] [13]	Endothelialization, inflammatory response, tissue integration [14]
Stimulation Capability	Focal cortical stimulation via stent electrodes [12]	Evoked motor responses, stimulation thresholds [12]

Clinical Translation Protocol

Clinical translation of the Stentrode system has followed a methodical pathway focused on safety and feasibility in human patients. The first-in-human study involved patients with amyotrophic lateral sclerosis (ALS) who received Stentrode implants via endovascular delivery to the superior sagittal sinus [2]. The implantation procedure was performed in a neurointerventional suite under general anesthesia, utilizing standard angiographic techniques [14]. Participants underwent postoperative training to control digital interfaces through motor imagery decoded from Stentrode-acquired signals [2]. The protocol included rigorous anticoagulation management, with dual antiplatelet therapy initiated prior to implantation and continued for 90 days [14]. Primary endpoints included device-related serious adverse events, system stability, and performance in controlling digital devices for communication [2]. Results from six ALS patients demonstrated successful use of the endovascular BCI for digital communication without major vascular complications, establishing preliminary safety and efficacy in a clinical population [2].

The Scientist's Toolkit: Essential Research Reagents and Materials

Advancing research in endovascular neural interfaces requires specialized materials and technical approaches. Table 3 catalogues key research reagents and their applications in developing and evaluating stent-electrode arrays.

Table 3: Essential Research Reagents and Materials for Endovascular Neural Interface Studies

Reagent/Material	Specifications	Research Application
Nitinol Alloy	Near-equiatomic nickel-titanium, laser-cut from drawn tubing [14]	Self-expanding stent scaffold with superelastic properties for deployment [14]
Platinum-Iridium Electrodes	90:10 or 80:20 composition, sputtered iridium oxide coating [14]	Neural recording sites with high corrosion resistance and charge injection capacity [14]
Polyimide Substrate	Biocompatible thin-film, lithographically patterned [14]	Flexible backbone for electrode arrays and trace insulation [14]
Parylene-C Dielectric	Vapor-deposited conformal coating [14]	Electrical insulation to prevent crosstalk and signal leakage [14]
Dual Antiplatelet Regimen	Aspirin and clopidogrel (90 days), then aspirin monotherapy [14]	Thromboembolic risk mitigation during endothelialization phase [14]
Laser Welding System	High-precision for micro-wire joining (25μm wires to 300μm pads) [13]	Device fabrication enabling smaller diameter constructs for thin vessels [13]

Current Research Directions and Future Applications

Technological Advancements

Current research in endovascular neural interfaces focuses on overcoming remaining limitations and expanding clinical applications. Miniaturization represents a key frontier, with recent investigations demonstrating laser-welded micro-wire stent electrodes as small as 25μm, enabling deployment in smaller vessels and compatibility with rodent models [13]. Signal processing innovations are critical for handling increasing channel counts, with emphasis on real-time, hardware-efficient algorithms for spike detection, feature extraction, and data compression to manage bandwidth constraints in wireless systems [15]. Future directions include the development of high-density endovascular arrays with increased electrode counts for improved spatial resolution, closed-loop systems capable of responsive stimulation, and integration with other neuromodulation approaches [2] [12]. Additionally, researchers are exploring novel electrode materials and coatings to enhance long-term signal stability and reduce impedance [13].

Clinical Expansion Pathways

The clinical translation pathway for endovascular neural interfaces continues to expand beyond the initial application in motor restoration for paralyzed patients. Current investigations explore potential applications in epilepsy monitoring and treatment, depression therapy through stimulation of mood-regulating circuits, stroke rehabilitation, and management of movement disorders [12]. The minimally invasive nature of endovascular approaches makes them particularly suitable for conditions where the risk-benefit ratio favors less invasive options [12]. Future clinical success will depend on demonstrating long-term safety and efficacy, optimizing patient selection criteria, refining implantation techniques, and developing intuitive decoding algorithms that maintain performance over chronic implantation periods [2]. As the technology matures, endovascular neural interfaces may offer a versatile platform for both recording and stimulating neural circuits across a broad spectrum of neurological and psychiatric conditions.

Core Components and Design Fundamentals of Stent-Electrode Arrays

Endovascular stent-electrode arrays represent a paradigm shift in neural interface technology, enabling direct recording and stimulation of brain activity from within the cerebral vasculature. Unlike traditional brain-computer interfaces (BCIs) that require open-brain surgery, these devices leverage minimally invasive endovascular techniques to position electrode arrays in blood vessels adjacent to target neural regions [2] [14]. This approach significantly reduces surgical trauma while maintaining signal fidelity comparable to traditional implanted arrays [3]. The Stentrode system, developed by Synchron, has emerged as a leading platform in this domain, demonstrating feasibility in both preclinical and clinical settings [14]. This application note details the core components, design fundamentals, and experimental methodologies underlying stent-electrode array technology, providing researchers with a comprehensive framework for development and implementation within neural recording research.

The architecture of a stent-electrode array is a sophisticated integration of medical device engineering, materials science, and neural electronics. The system is designed to navigate the human vasculature and chronically interface with neural tissue through the vessel wall. The fundamental components work in concert to achieve stable, long-term neural recording and stimulation.

Table 1: Core Components of a Stent-Electrode Array System

Component	Description	Material & Specifications	Primary Function
Stent Scaffold	Self-expanding mechanical backbone	Nitinol (Nickel-Titanium alloy), ~40mm length, ~8mm diameter [14]	Provides structural support, enables catheter-based delivery, and anchors the device within the target vessel.
Electrode Array	Thin-film array of recording/stimulation sites	Platinum-Iridium coated with Iridium Oxide; 16 electrodes; embedded on polyimide film [14]	Acquires neural signals (e.g., electrocorticography) and delivers electrical stimulation.
Lead Wires	Flexible, insulated electrical conduits	Helically wound conductors in silicone/polyurethane sheath [14]	Transmits signals from the intravascular electrode array to the subcutaneous telemetry unit.
Implantable Telemetry Unit (IRTU)	Subcutaneous signal processing and transmission module	Titanium-encased with low-noise amplifiers, ADC, and BLE telemetry [14]	Digitizes, powers, and wirelessly transmits neural data to external equipment.
External Telemetry Unit (ETU)	External communication and power module	Contains primary coil and receiver; worn over subclavicular region [14]	Provides inductive power to the IRTU and receives transmitted neural data.

The stent scaffold serves as the mechanical foundation. Fabricated from nitinol for its superelastic and shape-memory properties, it can be compressed into a delivery catheter and self-expand upon deployment to appose the vessel wall [14]. The electrode array is lithographically patterned onto a flexible polyimide substrate, which is then bonded to the stent's luminal surface. The choice of platinum-iridium and iridium oxide coating is critical for maximizing charge injection capacity and ensuring electrochemical stability during chronic implantation [14] [6].

Chronic biostability is achieved through endothelialization, where the stent and electrodes become covered by migrating endothelial cells, typically within four weeks. This process integrates the device into the vessel wall, stabilizing the interface and minimizing thromboembolic risk, which is further managed with dual antiplatelet therapy [14]. The telemetry system is designed for fully implantable, chronic operation. The IRTU is powered via inductive coupling from the ETU, eliminating percutaneous wires and reducing infection risk. The entire system is engineered to balance performance with long-term biocompatibility and patient safety [14].

Research Reagent Solutions and Essential Materials

The development and experimental validation of stent-electrode arrays require a specific set of materials, reagents, and equipment. The following toolkit outlines the essential resources for research in this field.

Table 2: Research Reagent Solutions for Stent-Electrode Array Development & Testing

Category	Item	Function/Application
Device Fabrication	Nitinol tubing	Laser-cut to form the base stent scaffold structure [14].
	Sputter deposition system	For applying platinum-iridium and platinum black coatings to electrodes [6].
	Polyimide film	Flexible substrate for patterning thin-film electrode arrays and conductive traces [14].
Electrochemical Characterization	Potentiostat/Galvanostat	For performing cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) [6].
	Phosphate Buffered Saline (PBS) or 0.9% Saline	Electrolyte solution for in vitro electrochemical testing [6].
	Ag/AgCl Reference Electrode	Essential component for a three-electrode electrochemical testing setup [6].
Preclinical & Biological Testing	Ovine models	Preferred in vivo model for feasibility and safety studies due to comparable cerebral venous anatomy [2] [3].
	Dual Antiplatelet Therapy (DAPT)	Standard pharmacological regimen (e.g., Aspirin and Clopidogrel) to mitigate thrombosis risk post-implantation [14].
	Histological staining reagents	For assessing tissue response, endothelialization, and device biocompatibility post-explant [14].

Detailed Experimental Protocols

Protocol: In Vitro Electrochemical Characterization of Stent-Electrode Arrays

Objective: To quantitatively evaluate the electrochemical performance and stability of stent-electrode arrays, focusing on metrics critical for neural recording and stimulation [6].

Materials:

• Potentiostat with three-electrode setup capability.
• Stent-electrode array as the working electrode.
• Ag/AgCl reference electrode (sat. KCl) and platinum wire counter electrode.
• 0.9% saline solution (non-degassed) at 37°C to simulate the in vivo environment [6].

Methodology:

• Cyclic Voltammetry (CV):
  • Set the potentiostat to perform CV scans from 0 V → 0.8 V → -0.6 V at a scan rate of 50 mV/s [6].
  • Record a minimum of two cycles.
  • Data Analysis: Calculate the anodic and cathodic charge storage capacity (CSC) from the first cycle by integrating the current over the voltage sweep. This metric indicates the electrode's capacity for charge transfer.

• Electrochemical Impedance Spectroscopy (EIS):

  • Perform EIS at 0 V with a 10 mV amplitude across a frequency range of 1 Hz to 200 kHz [6].
  • Data Analysis: Fit the EIS data to an equivalent circuit model to determine parameters like electrode impedance at key frequencies (e.g., 1 kHz), which is directly related to signal quality in recording applications.

• Voltage Transient (VT) Measurements:

  • Apply a biphasic, cathodic-first current pulse (e.g., 250 µs phase width) at varying amplitudes [6].
  • Measure the resulting voltage waveform across the electrode.
  • Data Analysis: Calculate the access voltage (Ea), polarization voltage (Ep), and total voltage (Et). The maximum charge injection capacity (CIC) is determined as the charge density that can be injected while keeping the Ep within the water window (typically below -600 mV to avoid irreversible Faradaic reactions) [6].

• Accelerated Lifetime Testing:

  • Subject the electrode to a continuous stimulation paradigm (e.g., biphasic pulses at a set frequency) for an extended period (e.g., 7 days) at a defined percentage of its CIC [6].
  • Repeat the CV, EIS, and VT measurements post-testing to assess for degradation in electrochemical performance or physical integrity of the electrode coating.

Protocol: Preclinical Implantation and Neural Recording in Ovine Models

Objective: To assess the surgical feasibility, safety, and chronic neural recording capability of a stent-electrode array in a large animal model [2] [14] [3].

Materials:

• Sterile stent-electrode array and delivery catheter system.
• Animal model (e.g., adult sheep).
• Angiography suite with fluoroscopic guidance.
• Dual antiplatelet therapy regimen.
• External telemetry unit and data acquisition system.

Methodology:

• Preoperative Preparation:
  • Initiate dual antiplatelet therapy (e.g., Aspirin and Clopidogrel) prior to implantation to reduce thrombosis risk [14].
  • Anesthetize the animal and position it for femoral or jugular venous access.

• Endovascular Implantation:

  • Under fluoroscopic guidance, navigate a microcatheter through the venous system (e.g., via the jugular vein) into the target cerebral vessel, typically the superior sagittal sinus (SSS) overlying the motor cortex [14] [3].
  • Deploy the stent-electrode array within the target segment of the SSS.
  • Retract the delivery system and achieve hemostasis at the access site.

• Post-operative Care and Data Acquisition:

  • Continue antiplatelet therapy according to the study protocol.
  • Allow a period (e.g., 2-4 weeks) for endothelialization and signal stabilization [14].
  • Record neural data chronically by activating the implanted telemetry unit with the external unit. Focus on capturing signals during rest and during task-based behaviors (e.g., forced-choice movement tasks) to isolate motor-related neural activity [3].

• Terminal Studies and Histology:

  • At the study endpoint, perfuse the animal and explant the brain and surrounding vasculature.
  • Process the tissue for histological analysis (e.g., H&E staining) to evaluate vessel patency, degree of endothelialization, and any tissue response (e.g., inflammation, intimal hyperplasia) [14].

Protocol: Signal Processing and Motor Decoding from Endovascular Recordings

Objective: To translate raw neural signals acquired from the stent-electrode array into meaningful commands for external devices.

Methodology:

• Signal Preprocessing:
  • Acquire raw wideband data (e.g., 0.5 Hz to 7.5 kHz) from the telemetry system [14].
  • Apply band-pass filters to isolate specific signal components: low-frequency Local Field Potentials (LFP, ~1-100 Hz) and high-frequency activity (e.g., high-gamma band, 70-200+ Hz), which is correlated with neuronal spiking and motor intent [14].

• Feature Extraction:

  • Calculate the power in the high-gamma band over short, consecutive time windows (e.g., 100 ms). This time-frequency power is a primary feature for decoding motor activity [14].
  • Optionally, extract other features like LFP amplitude or raw spike snippets if signal quality permits.

• Decoding Algorithm Training:

  • Use machine learning algorithms (e.g., support vector machines, linear discriminant analysis, or deep learning models) to create a mapping between the extracted neural features and the corresponding motor states or kinematics [17].
  • Train the decoder on a labeled dataset where neural data is recorded simultaneously with observed motor behaviors (e.g., limb movement, attempted speech).

• Real-Time Closed-Loop Control:

  • Implement the trained decoder in a real-time system to continuously translate incoming neural features into control signals for an external actuator, such as a computer cursor or robotic limb [2] [3].
  • Provide visual feedback to the subject to create a closed-loop BCI system, which is essential for neuroprosthetic control and functional restoration.

Advanced Material and Stimulation Enhancements

A key area of development for stent-electrode arrays is improving their efficacy in neural stimulation, which requires higher charge injection capacities than recording. Recent research has focused on advanced electrode coatings to address this challenge.

Platinum Black Modification: Sputter-coating platinum electrodes with a layer of "platinum black" creates a nanostructured, high-surface-area coating. This modification dramatically improves electrochemical performance [6].

Table 3: Impact of Platinum Black Coating on Electrode Performance

Electrochemical Metric	Standard Platinum Electrode	Platinum Black Coated Electrode	Functional Implication
Charge Injection Capacity (CIC)	21.9 µC cm⁻² [6]	64.9 µC cm⁻² [6]	Enables safer and more effective neural stimulation with higher charge delivery.
Electrochemical Impedance (at 10 Hz)	Higher	Substantially Reduced [6]	Improves signal-to-noise ratio for recording and reduces power consumption for stimulation.
Polarization Voltage	Higher	Reduced [6]	Operates further from the electrochemical limits, enhancing safety and longevity.
Coating Stability	N/A	Stable after 7-day continuous stimulation [6]	Supports chronic use, which is essential for clinical applications.

Finite-element modeling of the neural activating function indicates that this increased CIC translates to a substantially greater electrode-neuron distance that can be effectively and safely stimulated, opening the possibility for a new, minimally invasive neural stimulation paradigm for conditions like Parkinson's disease and chronic pain [6].

The evolution of neurosurgery towards minimally invasive techniques represents a paradigm shift aimed at minimizing patient trauma while maintaining high surgical efficacy. Traditional open craniotomies, while effective, are associated with significant tissue disruption, longer recovery times, and higher complication rates [18]. The concept of minimizing harm, a principle attributed to Hippocrates, has found modern expression in techniques that achieve optimal surgical efficiency with reduced patient morbidity [18]. Within this context, endovascular stent-electrode arrays emerge as a revolutionary advancement, enabling sophisticated neural recording and intervention without the substantial risks of conventional brain surgery. This document explores the quantified benefits of minimally invasive approaches and provides detailed protocols for their implementation in neural interface research.

Quantitative Analysis: Minimally Invasive vs. Traditional Approaches

Clinical studies across multiple neurosurgical applications consistently demonstrate the superior safety profile and enhanced recovery outcomes associated with minimally invasive techniques compared to traditional craniotomies.

Table 1: Comparative Outcomes of Surgical Approaches for Hypertensive Intracerebral Hemorrhage

Parameter	Minimally Invasive Endoscopic Surgery (Research Group)	Traditional Craniotomy (Control Group)	P-value
Operative Time (hours)	1.86 ± 0.65	5.54 ± 1.03	<0.05
Hematoma Clearance Rate (%)	83.43 ± 4.67	72.78 ± 9.35	<0.05
Intraoperative Blood Loss (mL)	61.06 ± 8.65	76.25 ± 10.12	<0.05
Post-op Bleeding (mL)	8.62 ± 1.1	17.41 ± 3.0	<0.05
Post-op Edema Around Hematoma (mL)	5.74 ± 1.36	10.13 ± 2.3	<0.05
Good Recovery (Glasgow Outcome Scale IV/V) (%)	90.7%	60.0%	<0.05

Source: Adapted from [19]

Table 2: Complication Rates by Treatment Modality for Unruptured Intracranial Aneurysms

Treatment Modality	Overall Complication Rate (%)	Key Characteristics
Minimally Invasive Craniotomy (MIC)	12.2 (pooled)	Favorable balance of safety and applicability; superior cosmetic outcomes [20].
Supraorbital (SOC) / Mini-pterional (MPC)	1.6 - 5.88 (individual studies)	Low individual study rates, particularly for anterior circulation aneurysms [20].
Simple Coiling	10.8	Lower procedural risk but higher recurrence and retreatment rates [20].
Balloon-Assisted Coiling	11.7
Flow Diverter	17.0	Higher complication rate but lower retreatment rate [20].
Stent-Assisted Coiling	37.0	Highest complication rate among endovascular options [20].

Source: Adapted from [20]

Table 3: Operative and Cosmetic Outcomes for Anterior Circulation Aneurysms

Outcome Metric	Supraorbital Minicraniotomy (SOMC)	Pterional Craniotomy (PC)	P-value
Operative Time (minutes)	213.9 ± 11.09	268.6 ± 15.44	0.0081
Cosmetic Satisfaction (VAS Score 0-100)	94.12 ± 1.92	83.57 ± 4.75	0.036
Aneurysm Clipping Success Rate	No significant difference (p=0.77)	No significant difference (p=0.77)	0.77

Source: Adapted from [21]

Experimental Protocols for Minimally Invasive Neural Recording

Protocol: Preoperative Targeting and Imaging for BCI Implantation

Objective: To precisely identify and target the primary motor cortex for the placement of neural recording devices using multi-modal imaging.

Background: Accurate localization is critical as missing the target by even a few millimeters can result in failure to record from critical neurons, given that representations of the thumb and pinky finger are separated by only approximately 6 mm in the primary motor cortex [22].

Materials:

• Magnetic Resonance Imaging (MRI) scanner
• Functional MRI (fMRI) capabilities
• High-density Electrocorticography (hd-ECoG) array (for intraoperative mapping)
• Neuronavigation system

Procedure:

• Pre-operative Structural and Functional MRI:
  • Acquire a high-resolution structural MRI scan to identify neuroanatomical landmarks.
  • Perform functional MRI (fMRI) while the patient executes or imagines specific motor tasks (e.g., hand movements). For sensory mapping, apply tactile stimuli or have the patient imagine them if somatosensation is impaired [22].
  • Co-register the fMRI data with the structural MRI to create a fused map identifying the target brain regions.

• Intraoperative Functional Mapping (Optional but Recommended):
  • Following the exposure of the cortical surface, place a high-density ECoG grid.
  • For patients with intact sensation, provide vibrotactile stimulation to relevant body regions (e.g., fingers) [22].
  • Record the hd-ECoG signals in real-time to localize the precise functional areas, such as finger representations in the S1 cortex [22].
  • Use this data to guide the final placement of the microelectrode array for chronic recording.

Validation: The accuracy of targeting should be confirmed intraoperatively through the observed neural responses and post-operatively via follow-up imaging and initial signal quality assessment.

Protocol: Endovascular Stentrode Implantation for Chronic Neural Recording

Objective: To safely implant an endovascular stent-electrode array (Stentrode) in the superior sagittal sinus for long-term, high-fidelity neural recording without open craniotomy.

Background: This minimally invasive approach utilizes the venous system for electrode placement, significantly reducing surgical risk and recovery time compared to traditional cortical array implantation [2].

Materials:

• Stentrode device (stent-electrode array)
• Biplanar angiography suite
• Microcatheter system
• Jugular vein access kit (ultrasound, needle, guidewire)
• Fluoroscopic imaging equipment
• Continuous physiological monitoring equipment

Procedure:

• Venous Access:
  • Under ultrasound guidance, achieve percutaneous access to the jugular vein [23].
  • Insert a guidewire and advance an introducer sheath.

• Navigation and Deployment:

  • Under fluoroscopic guidance, navigate a microcatheter through the venous system until its tip is positioned in the superior sagittal sinus, adjacent to the primary motor cortex [2] [23].
  • Carefully advance the Stentrode device through the microcatheter.
  • Deploy the self-expanding Stentrode within the target vein, securing the electrodes in apposition with the vessel wall [23].

• Post-Procedural Monitoring and Validation:

  • Confirm the final device position and vessel patency post-deployment.
  • Monitor the patient for acute complications, such as thrombosis or vessel injury. Long-term studies in ovine and human trials have shown a stable implant with minimal vascular complications [2].
  • Initiate neural recording sessions to validate signal quality, which has been shown to rival that of subdural arrays [2].

Visualizing Workflows and Risk Mitigation

Minimally Invasive Risk Reduction Pathway

Endovascular BCI Implantation Workflow

The Scientist's Toolkit: Research Reagent Solutions

Table 4: Essential Materials for Minimally Invasive Neural Interface Research

Item	Function/Benefit
Stentrode (Endovascular BCI)	A stent-based electrode array delivered via blood vessels enabling neural recording without craniotomy [2] [23].
High-Channel-Count Microelectrode Arrays	Devices from companies like Blackrock Neurotech (Neuralace) and Paradromics (Connexus) providing high-fidelity recording from hundreds to thousands of neurons [22] [23].
Thin-Film Cortical Arrays	Ultra-thin, flexible electrode arrays (e.g., Precision Neuroscience's Layer 7) that conform to the cortical surface with minimal invasion [23].
Neuro-Navigation System	GPS-like computer guidance for precise surgical planning and smaller, targeted cranial openings [18] [24].
Neuroendoscope	A tiny camera providing real-time illumination and visualization of deep brain structures through small openings [18] [24].
Laser Ablation System	Enables Laser Interstitial Thermal Therapy (LITT), a less invasive alternative to open surgery for tumor ablation [24].

Implementation and Clinical Workflow of Stentrode Technology

The development of endovascular stent-electrode arrays represents a paradigm shift in minimally invasive neural recording research, offering a transformative approach to understanding brain function and treating neurological disorders. These innovative devices are designed to be delivered via the blood vessels to record neural activity or stimulate specific brain regions, eliminating the need for open brain surgery [25]. The successful translation of such advanced neurotechnology from concept to clinical application hinges on rigorous preclinical validation using appropriate animal models that can accurately predict human responses. This article examines the complementary roles of established rodent models and large animal ovine models in the preclinical development pipeline for endovascular neural interfaces, providing researchers with detailed insights into model selection, experimental protocols, and validation methodologies.

Rodent models, particularly rats and mice, have long served as the foundational platform for initial proof-of-concept studies and mechanistic investigations in neuroscience research. Their short reproductive cycles, well-characterized neuroanatomy, and genetic tractability make them invaluable for early-stage device development and hypothesis testing [26]. In contrast, sheep (Ovis aries) have emerged as particularly relevant large animal models for validating neural interface technologies destined for human application. Sheep possess brains more comparable in size and anatomy to humans, with a gyrencephalic cortex, well-defined basal ganglia nuclei, and similar cerebrospinal fluid volume dynamics [27]. The average adult sheep brain weighs 130-140g, substantially closer to the human brain (1,300-1,400g) than the rodent brain (1-2g), providing a more realistic environment for testing endovascular devices designed for human neurovasculature [27].

Furthermore, the docile nature of sheep and their ability to be trained for cognitive tasks enable sophisticated in vivo monitoring techniques including electroencephalography (EEG), electromyography (EMG), and magnetic resonance imaging (MRI) in awake, freely-moving subjects [27]. These capabilities are particularly valuable for assessing the functional performance of endovascular neural interfaces over extended periods, which is essential for chronic implantation studies. The following sections provide a comprehensive overview of the specific applications, methodological protocols, and validation criteria for both rodent and ovine models in the context of endovascular neural interface research.

Comparative Analysis of Preclinical Models

The selection of an appropriate animal model represents a critical decision point in the preclinical development pathway for endovascular neural interfaces. Each model system offers distinct advantages and limitations that must be carefully balanced against specific research objectives, regulatory requirements, and translational goals. The table below provides a systematic comparison of key characteristics between rodent and ovine models relevant to neural interface development.

Table 1: Comparative Analysis of Rodent and Ovine Models for Neural Interface Research

Characteristic	Rodent Models (Rats/Mice)	Ovine Models (Sheep)
Brain Mass	1-2 g	130-140 g
Cortical Structure	Lissencephalic (smooth)	Gyrencephalic (folded)
Neurovascular Anatomy	Simplified vascular complexity	Complex, similar to human cerebral vasculature
Lifespan	1.5-3 years	9-12 years
In Vivo Monitoring	Limited in awake models; requires restraint	Comprehensive EEG, EMG, MRI in awake, freely-moving subjects
Chronic Study Feasibility	Short-term (weeks to months)	Long-term (months to years)
Regulatory Pathway	Early-stage feasibility and biocompatibility	Advanced safety and efficacy for regulatory submissions
Genetic Engineering	Well-established transgenic methodologies	Emerging capabilities (e.g., CRISPR-Cas9)
Cost Considerations	Lower per animal cost, higher subject numbers	Higher per animal cost, fewer subjects
Translational Fidelity	Moderate for basic mechanisms	High for device deployment and surgical techniques

The gyrencephalic organization of the sheep cerebral cortex, with its characteristic folds and sulci, more closely recapitulates the human neuroanatomical landscape compared to the lissencephalic rodent brain [27]. This structural similarity extends to the cerebrovasculature, where sheep exhibit comparable vessel diameter, branching patterns, and flow dynamics to humans—particularly relevant for endovascular device deployment. Additionally, the longer natural lifespan of sheep enables longitudinal studies that can assess the chronic performance, stability, and biocompatibility of implanted neural interfaces over clinically relevant timeframes, which is essential for devices intended for long-term human use [27].

Rodent Models in Early-Stage Device Development

Applications and Experimental Design

Rodent models serve as indispensable tools during the initial phases of endovascular neural interface development, providing a cost-effective platform for evaluating fundamental device properties, biological responses, and recording capabilities. Their primary applications include first-in-animal device feasibility studies, preliminary biocompatibility assessments, and optimization of surgical implantation techniques. The relatively simple neurovasculature of rodents enables rapid prototyping and iterative device refinement before progressing to more complex large animal models. Furthermore, the availability of well-characterized disease models in rodents permits initial validation of neural recording and stimulation efficacy in pathological states, establishing proof-of-concept for therapeutic applications [26].

The experimental design for rodent studies must incorporate appropriate controls, randomization procedures, and blinding techniques to minimize potential biases, particularly when assessing functional outcomes or histological endpoints. For endovascular device evaluations, study designs typically include sham-operated control groups that undergo identical surgical procedures without device implantation to account for procedural trauma and inflammatory responses. Sample size calculations should be based on preliminary data or established effect sizes from similar interventions to ensure sufficient statistical power. The study timeline must incorporate appropriate acclimation periods, postoperative recovery intervals, and predefined experimental endpoints that align with the specific research objectives, whether acute functional assessment or chronic biocompatibility evaluation [28].

Detailed Surgical Protocol: Rodent Model

Objective: To establish a standardized surgical protocol for the implantation of endovascular stent-electrode arrays in a rodent model for acute neural recording studies.

Materials:

• Custom-designed endovascular stent-electrode array (e.g., platinum electrodes on self-expanding nitinol stent)
• Vascular access introducer sheath (appropriate gauge for rodent vessels)
• Fluoroscopic guidance system (e.g., mini C-arm for real-time visualization)
• Surgical microscope for enhanced visualization
• Anesthesia delivery system with isoflurane and oxygen
• Physiological monitoring equipment (body temperature, respiratory rate, blood oxygenation)
• Sterile surgical instruments (micro-scissors, forceps, vessel dilators, needle holders)
• Vascular closure supplies (fine sutures, hemostatic agents)
• Postoperative analgesia and recovery supplies

Preoperative Preparation:

• Anesthetize the animal using inhaled isoflurane (3-5% for induction, 1-3% for maintenance) in oxygen, delivered via nose cone.
• Secure the animal in supine position on a heated surgical platform to maintain body temperature at 37°C.
• Apply ophthalmic ointment to prevent corneal drying during prolonged anesthesia.
• Administer preoperative analgesics (e.g., buprenorphine, 0.05 mg/kg subcutaneously) 30 minutes prior to incision.
• Shave and aseptically prepare the surgical site (neck region) using alternating scrubs of chlorhexidine and isopropyl alcohol.
• Drape the surgical site with sterile barriers, maintaining a sterile field throughout the procedure.

Surgical Procedure:

• Make a midline cervical incision approximately 2-3 cm in length using a sterile scalpel.
• Carefully dissect through subcutaneous tissues using blunt dissection to expose the common carotid artery.
• Isolate a 1-1.5 cm segment of the carotid artery, carefully preserving the vagus nerve.
• Administer heparin (100 IU/kg intravenously) to prevent thrombus formation during vascular access.
• Place proximal and distal ligatures around the isolated carotid segment but do not tighten.
• Make a small arteriotomy in the carotid artery using micro-scissors.
• Introduce a vascular access sheath into the arteriotomy site and advance it retrograde toward the aortic arch.
• Under fluoroscopic guidance, navigate the endovascular stent-electrode array through the sheath and position it in the target cerebral vessel (typically the internal carotid artery or middle cerebral artery).
• Deploy the stent-electrode array according to manufacturer specifications, ensuring full apposition to the vessel wall.
• Carefully withdraw the delivery system while maintaining the position of the deployed device.
• Remove the access sheath and ligate the carotid artery distal to the access site.
• Irrigate the surgical field with sterile saline and close the incision in layers using appropriate sutures or wound clips.

Postoperative Care:

• Monitor animals continuously until fully recovered from anesthesia.
• Administer postoperative analgesics every 6-12 hours for at least 48 hours.
• Provide supplemental warmth and soft food during recovery period.
• Monitor incision sites daily for signs of infection or dehiscence.
• Allow minimum 7-day recovery period before initiating experimental recordings.

This protocol can be adapted for chronic implantation studies by incorporating sterile technique refinements and aseptic practices throughout the procedure. For longitudinal assessments, animals should be monitored regularly for signs of neurological deficit, infection, or weight loss, with predefined criteria for early intervention or humane endpoints.

Data Collection and Analytical Methods

Comprehensive data collection in rodent models encompasses multiple domains, including device performance, neural signal quality, histological compatibility, and functional outcomes. Neural recording assessments should include quantitative measures of signal-to-noise ratio, electrode impedance, and the presence of physiological neural signatures such as local field potentials, single-unit activity, or event-related potentials. Histological evaluations typically focus on the tissue response at the device-tissue interface, including measures of endothelialization, inflammatory cell infiltration, glial activation, and neuronal integrity adjacent to the implanted device. Immunohistochemical staining for specific markers (e.g., Iba-1 for microglia, GFAP for astrocytes, NeuN for neurons) provides detailed characterization of the cellular response to the implanted device [26].

Functional assessments may include behavioral testing, motor evoked potentials, or sensory processing tasks that can be correlated with neural recording data. For studies incorporating electrical stimulation through the endovascular interface, additional parameters must be monitored, including stimulation thresholds, charge injection capacity, and potential tissue damage associated with stimulation protocols. The analytical approach should incorporate appropriate statistical methods for comparing experimental groups, with particular attention to longitudinal data analysis and multiple comparison adjustments when appropriate. All data collection procedures should be documented in detailed standard operating procedures to ensure consistency across experimental sessions and between different operators [28].

Ovine Models in Advanced Preclinical Validation

Applications and Experimental Design

Ovine models serve as a critical translational bridge between initial rodent studies and human clinical trials for endovascular neural interfaces, providing a robust platform for evaluating device safety, efficacy, and long-term performance in a neuroanatomical context that closely approximates the human condition. The applications of ovine models specifically include validation of surgical implantation techniques using clinically relevant endovascular approaches, assessment of chronic device stability and biocompatibility over extended periods, and evaluation of neural recording fidelity in a gyrencephalic brain with complex neurovascular anatomy [27]. Furthermore, the similar body size and vascular dimensions of sheep enable testing of human-scale devices and delivery systems, providing essential procedural training for neurointerventionalists before advancing to human trials.

The experimental design for ovine studies must incorporate rigorous safety endpoints and methodological refinements that align with regulatory requirements for device approval. Study designs typically include cohort groups with staggered sacrifice timepoints to characterize the temporal progression of the tissue response and device integration. For endovascular neural interfaces, key experimental groups often include short-term acute assessments (≤30 days) to evaluate initial device performance and procedural complications, intermediate-term cohorts (1-3 months) to assess device stability and mature tissue response, and long-term cohorts (≥6 months) to evaluate chronic biocompatibility and sustained recording functionality [28]. The inclusion of positive and negative control groups, when available, strengthens the study design and facilitates more meaningful interpretation of the histological and functional outcomes.

Detailed Surgical Protocol: Ovine Model

Objective: To establish a standardized surgical protocol for the implantation of endovascular stent-electrode arrays in an ovine model for chronic neural recording studies.

Materials:

• Commercial or investigational endovascular stent-electrode array (e.g., Stentrode or equivalent)
• Fluoroscopic angiography system with digital subtraction capability
• Vascular access introducer sheath (6-8 French)
• Microcatheter and guidewire system for neurovascular navigation
• General anesthesia delivery system with endotracheal intubation capabilities
• Physiological monitoring equipment (ECG, blood pressure, temperature, blood oxygenation)
• Automated perfusion fixation system for terminal histology
• Sterile surgical supplies and implantable recording telemetry system if applicable

Preoperative Preparation:

• Fast animals for 24 hours with free access to water prior to surgery.
• Administer preoperative antibiotics (e.g., procaine penicillin, 20 mg/kg intramuscularly) 30 minutes prior to procedure.
• Induce anesthesia using intravenous propofol (4-6 mg/kg) and maintain with inhaled isoflurane (1-2.5%) in oxygen.
• Intubate the animal and maintain mechanical ventilation throughout the procedure.
• Insert intravenous catheters for fluid administration and continuous physiological monitoring.
• Position the animal in lateral recumbency and shave the surgical site (groin region for femoral access).
• Perform thorough aseptic preparation of the surgical site using chlorhexidine scrub and alcohol.
• Administer heparin (100 IU/kg intravenously) after vascular access is established.

Surgical Procedure:

• Make a skin incision over the femoral artery and isolate the vessel using blunt dissection.
• Perform femoral artery puncture using Seldinger technique and place an introducer sheath.
• Under fluoroscopic guidance, navigate a guidewire and microcatheter system through the vascular system to the target cerebral vessel (typically the superior sagittal sinus or cortical veins).
• Perform diagnostic angiography to confirm appropriate vascular anatomy and device sizing.
• Navigate the endovascular stent-electrode array through the microcatheter to the target implantation site.
• Deploy the device under fluoroscopic visualization, ensuring complete expansion and wall apposition.
• Confirm device position and patency of the vessel using post-deployment angiography.
• Connect the electrode leads to a subcutaneous telemetry unit or externalized connector system.
• Remove the introducer sheath and achieve hemostasis at the access site using manual compression or vascular closure device.
• Close the surgical incision in layers using absorbable sutures.
• Apply sterile dressing to the incision site.

Postoperative Care:

• Monitor animals continuously in a recovery area until standing and alert.
• Administer postoperative analgesics (e.g., meloxicam, 0.5 mg/kg daily) for 3-5 days.
• Provide prophylactic antibiotics for 3-5 days postoperatively.
• Monitor incision sites daily for signs of infection or dehiscence.
• Allow 14-day recovery period before initiating experimental recordings for chronic studies.

This protocol can be adapted for specific research objectives, including different implantation targets, recording durations, or combination therapies. The surgical approach should be performed by or in collaboration with an experienced neurointerventionalist to ensure technical proficiency and appropriate device deployment.

Data Collection and Analytical Methods

Comprehensive data collection in ovine models encompasses a multifaceted approach that includes device performance metrics, neural recording quality, histological compatibility, and large animal-specific physiological parameters. Neural signal assessment should include quantitative measures of signal-to-noise ratio across multiple frequency bands, electrode impedance spectroscopy, and the capability to record task-evoked neural responses during cognitive or motor paradigms. Angiographic evaluations performed at implantation and explanation timepoints provide critical information about device stability, vessel patency, and potential thrombus formation or neointimal hyperplasia [6].

Histological analysis in ovine models requires specialized processing techniques due to the larger brain size, including sectioning protocols optimized for gyrencephalic tissue and appropriate sampling strategies to adequately characterize the device-tissue interface. Key histological endpoints include endothelialization of the device struts, inflammatory response (characterized by CD68+ macrophages and CD3+ lymphocytes), glial activation (GFAP+ astrocytes), and neuronal integrity in adjacent brain regions. For functional assessments, sheep can be trained to perform cognitive tasks or behavioral paradigms that provide clinically relevant correlates to human neurological function, enabling correlation between neural recording data and functional outcomes [27].

Advanced analytical techniques may include computational modeling of the electrode-neuron interface, finite element analysis of mechanical forces at the device-vessel wall interface, and machine learning approaches for decoding neural signals. The analytical framework should incorporate appropriate statistical methods for repeated measures and longitudinal data analysis, with sample sizes determined by power calculations based on preliminary data or established effect sizes from similar device evaluations. All analytical methods should be pre-specified in the study protocol to minimize potential biases in data interpretation [28].

Research Reagent Solutions and Materials

The successful execution of preclinical studies for endovascular neural interfaces requires access to specialized reagents, equipment, and analytical tools. The following table provides a comprehensive overview of essential research materials and their specific applications in the development and validation pipeline.

Table 2: Essential Research Reagents and Materials for Endovascular Neural Interface Studies

Category	Specific Items	Research Application
Electrode Materials	Platinum, Platinum-black coated electrodes, Iridium oxide	Neural recording and stimulation interfaces with enhanced charge injection capacity [6]
Stent Platform Materials	Nitinol (Nickel-Titanium alloy), Cobalt-Chromium alloys	Self-expanding stent platform for vessel apposition and electrode support
Delivery Systems	Microcatheters, Guidewires, Introducer sheaths	Endovascular navigation and device deployment
Characterization Equipment	Potentiostat, Electrochemical impedance spectroscopy systems	Electrochemical characterization and charge injection capacity measurement [6]
Imaging Modalities	Fluoroscopic angiography, MRI, Micro-CT	Device positioning, in vivo monitoring, and post-explant analysis
Histological Stains	H&E, Masson's Trichrome, CD68, GFAP, von Willebrand Factor	Tissue response evaluation, inflammation assessment, endothelialization
Neural Signal Processing	Multichannel acquisition systems, Spike sorting software, Spectral analysis tools	Neural signal recording, processing, and analysis
Surgical Supplies	Vascular access kits, Micro-dissection instruments, Sterile drapes	Surgical implantation and aseptic technique

Specific electrode materials warrant particular attention in the development of endovascular neural interfaces. Recent advances in electrode technology have demonstrated that platinum black coatings substantially increase charge injection capacity compared to uncoated platinum electrodes, with studies showing approximately threefold improvement (64.9 µC cm⁻² versus 21.9 µC cm⁻²) while maintaining electrochemical stability during continuous stimulation paradigms [6]. This enhanced performance is attributed to the increased electroactive surface area of the platinum black coating, which reduces impedance and polarization voltage during neural stimulation, thereby improving the safety and efficacy of the neural interface.

Visualizing Experimental Workflows and Signaling Pathways

The development and validation of endovascular neural interfaces involves complex experimental workflows and technological principles that benefit from visual representation. The following diagrams illustrate key processes and relationships in this research domain.

Diagram 1: Rodent Study Workflow for Neural Interface Development. This flowchart illustrates the sequential stages of early-stage device evaluation in rodent models, from initial device fabrication through data analysis and the decision point for advancement to large animal studies.

Diagram 2: Key Advantages of Ovine Models for Neural Interface Research. This diagram categorizes the principal benefits of sheep models into neuroanatomical, monitoring, and translational domains, highlighting their relevance for endovascular device validation.

The successful development of endovascular stent-electrode arrays for minimally invasive neural recording requires a strategic, phased approach that leverages the complementary strengths of both rodent and ovine preclinical models. Rodent models provide an efficient platform for initial device feasibility testing, mechanism of action studies, and rapid iterative design improvements, while ovine models offer a translationally relevant neuroanatomical and physiological environment for evaluating safety, chronic performance, and procedural techniques using human-scale devices. This integrated validation pathway ensures that only the most promising neural interface technologies advance to clinical trials, maximizing patient safety and accelerating the development of innovative solutions for neurological disorders.

The future of endovascular neural interface research will likely involve further refinement of both model systems, including the development of more sophisticated disease-specific models in both rodents and sheep that can better recapitulate the pathological states targeted by these therapeutic devices. Additionally, continued advances in electrode materials, such as platinum black coatings that enhance charge injection capacity, will improve the performance and longevity of these devices [6]. By adhering to rigorous preclinical validation protocols and leveraging the appropriate animal model for each stage of development, researchers can efficiently translate promising neural interface technologies from laboratory concepts to clinical applications that improve patient outcomes in neurological disease.

Endovascular stent-electrode arrays represent a paradigm shift in neural interface technology, offering a minimally invasive alternative to traditional cortical electrode implantation. By leveraging the body's natural vascular pathways, these devices avoid the need for open craniotomy, thereby reducing surgical morbidity, accelerating recovery, and minimizing the risk of tissue injury and inflammation [2] [14]. This procedure transforms the implantation of a high-fidelity brain-computer interface (BCI) from a neurosurgical operation into a neurointerventional procedure, comparable in scope to routine angiograms [14]. This application note provides a detailed, step-by-step protocol for the endovascular delivery of stent-electrode arrays, framed within contemporary research for the scientific community.

Pre-Procedural Planning and Anatomical Considerations

Successful implantation hinges on meticulous pre-procedural planning. The foundation of this process is a comprehensive anatomical assessment to determine the feasibility of access and optimal device positioning.

2.1 Vascular Access Route Mapping: The primary delivery path for most stent-electrode arrays, such as the Stentrode, extends from the internal jugular vein, through the sigmoid sinus, and into the superior sagittal sinus (SSS), which overlies the primary motor cortex [10] [14]. Researchers must utilize digital subtraction angiography (DSA) to characterize the patient-specific anatomy of the intracranial venous system, including vessel diameters, tortuosity, and the location of the target cortex relative to the SSS [10]. For example, the ovine model, commonly used in preclinical studies, has a sigmoid sinus diameter of approximately ~5.79 mm and a transverse sinus diameter of ~2.30 mm [10].

2.2 Device Selection: The choice of electrode array depends on the research objectives. For large-scale electrocorticography (ECoG) signals, stent-based electrodes (e.g., Stentrode) are deployed within large sinuses [14]. For recording single-unit spiking activity, ultra-flexible penetrating electrodes (e.g., uFINE-I) are designed to be delivered through the vessel wall into the brain parenchyma [10]. The table below summarizes key device characteristics.

Table 1: Comparison of Endovascular Neural Electrode Systems

Device / Study	Electrode Type / Material	Target Vessel / Region	Key Recording Capability	Subject
Stentrode [14]	16 Pt-Ir electrodes on nitinol stent	Superior Sagittal Sinus (Motor Cortex)	ECoG, High-gamma activity	Sheep, Human (ALS patients)
uFINE-I [10]	30-channel ultraflexible array (Polyimide)	Penetrating via confluence of sinuses to Occipital Lobe	Local Field Potentials & Single-Unit Spikes	Sheep
Osaka Univ. Tech. [29]	Ultra-thin wire electrodes	Cortical & Deep Veins	Somatosensory/Visual Evoked Potentials	Pig

Step-by-Step Implantation Protocol

The following protocol synthesizes techniques from established preclinical and clinical procedures for stent-electrode deployment.

3.1 Patient Preparation and Anesthesia. The subject is placed under general anesthesia. For chronic implants, a dual antiplatelet regimen (e.g., aspirin and clopidogrel) is typically administered prior to the procedure to mitigate the risk of thrombus formation [14].

3.2 Vascular Access and Guide Catheter Navigation.

• Step 1: Obtain percutaneous access to the internal jugular vein using the Seldinger technique.
• Step 2: Under continuous fluoroscopic guidance, advance a long introducer sheath or guide catheter through the sigmoid sinus and into the proximal segment of the superior sagittal sinus (SSS) [10] [14]. This establishes a stable conduit for the microcatheter and electrode system.

3.3 Microcatheterization and Device Delivery.

• Step 3: Navigate a neurointerventional microcatheter (e.g., with an outer diameter of 1.7 Fr / 0.57 mm) through the guide sheath and into the target position within the SSS [10]. For the Stentrode, the final position is confirmed to be adjacent to the motor cortex.
• Step 4 (For Stentrode-type Arrays): Deploy the self-expanding stent-electrode array from the microcatheter. The nitinol scaffold expands to achieve stable apposition against the venous endothelium, ensuring electrode contact [14].
• Step 4 (For Penetrating Electrodes like uFINE-I): This requires a more complex system. A piercing device comprising a microneedle and a guiding microwire is advanced through the microcatheter. The microneedle is used to penetrate the vessel wall at a predetermined site (e.g., the confluence of sinuses). The ultraflexible electrode, hitched to the guiding microwire, is then inserted through the penetration and advanced into the target brain tissue [10].

3.4 Lead Routing and Telemetry Unit Implantation.

• Step 5: After electrode deployment, the proximal connection lead is carefully retracted back through the venous system and tunneled subcutaneously to a surgically created pocket, typically in the infraclavicular region.
• Step 6: The lead is connected to a subcutaneous Implantable Receiver-Transmitter Unit (IRTU). This unit, housed in a hermetically sealed titanium case, contains the electronics for low-noise signal amplification, digitization, and wireless data transmission via an external telemetry unit [14].

The following diagram illustrates the core workflow of the endovascular delivery procedure.

Experimental Validation and Signal Recording Protocols

Following implantation, the functionality of the neural interface must be validated through a series of experimental protocols.

4.1 Signal Acquisition and Processing. Neural signals are acquired from the electrode array by the IRTU, which typically performs initial amplification and analog-to-digital conversion at sampling rates of ≥1 kHz per channel to capture high-frequency components like high-gamma ECoG activity [14]. The digitized data is then transmitted wirelessly to an external computer for further processing, including filtering (e.g., 0.5-300 Hz for LFP, 300-5000 Hz for spiking activity) and decoding [10] [14].

4.2 Functional Task Validation.

• Motor Paradigms: In subjects with motor cortex implants, researchers can design tasks where movement intention is decoded from the recorded signals. For instance, in clinical trials with paralyzed patients, signals from the Stentrode were used to control digital interfaces for communication, achieving multiple mouse-click actions and cursor navigation [2] [14].
• Sensory Evoked Potentials: For electrodes placed in sensory areas (e.g., the visual cortex), responses to external stimuli can be recorded. The uFINE-I device in the sheep occipital lobe successfully recorded visually evoked responses, while the Osaka University team recorded somatosensory evoked potentials from cortical veins and visual evoked potentials from deep cerebral veins [29] [10].

The workflow for experimental validation is outlined below.

The Scientist's Toolkit: Essential Materials and Reagents

The following table details key materials and reagents required for the implantation and validation of endovascular neural interfaces.

Table 2: Research Reagent Solutions for Endovascular BCI Implantation

Item Name	Function / Application	Specifications / Examples
Stent-Electrode Array	Neural signal recording from within blood vessels	Self-expanding nitinol stent with integrated Pt-Ir electrodes [14]; Ultraflexible polyimide array (uFINE-I) [10].
Neurointerventional Microcatheter	Delivery conduit for navigating cerebral venous system	~1.7 Fr (0.57 mm) outer diameter, ~400 mm length [10].
Guide Sheath	Stable access from percutaneous entry point to proximal target sinus	Standard neurointerventional introducer sheaths.
Anti-platelet Agents	Thrombosis prophylaxis for chronic intravascular implants	Dual therapy: Aspirin & Clopidogrel (typically for 90 days) [14].
Contrast Agent	Visualization of vasculature during DSA and navigation	Iso-osmolar, non-ionic iodinated contrast media.
Implantable Telemetry Unit	Subcutaneous signal amplification, digitization, and wireless transmission	Hermetically sealed titanium enclosure, inductive powering, Bluetooth Low Energy protocol [14].

Troubleshooting and Common Technical Challenges

Despite the minimally invasive nature, researchers may encounter specific challenges.

• Signal Quality Issues: Poor signal-to-noise ratio may result from suboptimal electrode contact with the vessel wall. Ensure the stent is fully expanded. Post-implantation, signal stability improves as the device endothelializes over several weeks [14].
• Thrombosis Risk: The presence of a foreign body in the venous system necessitates strict adherence to antiplatelet regimens. Monitor for signal degradation that may indicate thrombus formation [2] [14].
• Anatomical Constraints: Significant anatomical variability may preclude access in some subjects, underscoring the critical importance of pre-procedural DSA screening [2] [10].
• Penetration Challenges (for uFINE-I): Penetrating the venous wall requires precise control. The use of a balloon catheter to temporarily stabilize the deployment system relative to the vessel wall can enhance precision [10].

Endovascular stent-electrode arrays, such as the Stentrode, represent a paradigm shift in brain-computer interface (BCI) technology by providing a minimally invasive method for acquiring high-fidelity neural signals [2]. Unlike traditional invasive methods that require open craniotomy, endovascular BCIs are delivered via the cerebral venous system, typically navigating to the superior sagittal sinus to position electrodes over cortical regions of interest, such as the motor cortex [3]. This approach significantly reduces surgical risk and recovery time while enabling chronic implantation for long-term neural recording [2] [3]. The fundamental principle involves using the body's natural vascular pathways as a conduit for placing electrodes that can record electrocorticography (ECoG)-like signals from within blood vessels, achieving a favorable trade-off between invasiveness and signal resolution [3].

The clinical motivation for this technology is substantial. Patients with conditions such as amyotrophic lateral sclerosis (ALS), spinal cord injuries, or stroke sequelae often experience prolonged loss of motor function and communication capacity. Endovascular BCIs offer a potential pathway to restore digital communication and device control by translating neural activity into commands for external devices [2]. Early clinical studies have demonstrated that patients with severe paralysis can successfully use endovascular BCIs for digital communication, highlighting the transformative potential of this technology for neurological rehabilitation and assistive devices [2].

Signal Acquisition Technologies

Endovascular Electrode Systems

The core component of an endovascular BCI is the stent-electrode array, a minimally invasive device combining a self-expanding stent scaffold with multiple embedded electrodes. This design provides both mechanical support within the blood vessel and a platform for neural signal acquisition.

Table: Key Characteristics of Endovascular Stent-Electrode Arrays

Feature	Specification	Functional Significance
Delivery Method	Minimally invasive catheter-based delivery via venous system [2]	Avoids open craniotomy; reduces surgical complications and recovery time
Typical Deployment Site	Superior sagittal sinus adjacent to motor cortex [3]	Targets regions controlling voluntary movement for motor BCI applications
Number of Electrodes	Varies (e.g., 16 or more electrode contacts) [3]	Determines spatial resolution and coverage area for neural recording
Electrode Material	Platinum cobalt, platinum-iridium, or similar biocompatible metals [3]	Provides optimal electrochemical properties for recording while minimizing tissue reaction
Chronic Implantation	Several months to years demonstrated in animal and human studies [2]	Enables long-term stable recording; endothelialization improves signal stability

The acquisition of neural signals via endovascular approaches offers distinct advantages. Historically, researchers demonstrated that endovascular electrodes could record signals 2-5 times stronger than scalp EEG, with comparable fidelity to subdural arrays but with substantially reduced invasiveness [3]. The electrical signal becomes more stable after the electrode fuses with the vascular endothelium, whereas traditional invasive electrodes implanted in brain tissue may suffer from signal degradation due to gliosis [3].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table: Essential Materials for Endovascular BCI Research

Item	Function	Application Notes
Stentrode Device	Self-expanding stent with electrode array for chronic neural recording [2]	Deployed in superior sagittal sinus; requires endovascular surgical expertise
Neuropixels Probes	High-density neural probes for validation studies [30]	Used in parallel for ground-truth comparison of signal quality
Biocompatible Coatings	(e.g., polytetrafluoroethylene) to improve biocompatibility [3]	Reduces thrombotic risk and improves long-term integration
Anticoagulant Regimen	Standard post-stent implantation medication [3]	Mitigates thrombosis risk; dual anticoagulation may be required initially
High-Speed Video System	300Hz capture for behavioral correlation [30]	Synchronized with neural data for movement-related activity analysis

Signal Processing Pipeline

The transformation of raw neural signals into decoded commands involves a multi-stage processing pipeline that leverages advanced computational techniques to extract meaningful information from complex neural data.

Preprocessing and Noise Filtering

The initial processing stage addresses the challenge of extracting low-amplitude neural signals from noisy physiological and environmental interference. For endovascular recordings, this includes:

• Bandpass filtering (typically 0.5-300Hz) to remove DC drift and high-frequency noise while preserving physiological signals of interest [31]
• Notch filtering at 50/60Hz to eliminate line noise interference
• Artifact rejection algorithms to identify and remove contamination from sources such as motion, muscle activity, or cardiac cycles [31]

The stability of the chronic implant position of endovascular electrodes provides an advantage in signal consistency compared to some invasive approaches, as the fixed relationship to neural tissue reduces motion-related artifacts once endothelialization occurs [3].

Feature Extraction and Decoding Methods

Advanced feature extraction and classification methods enable the translation of preprocessed neural signals into meaningful commands. Contemporary approaches include:

• Decomposition algorithms used in approximately 50% of modern BCI studies to separate neural signals into constituent components [31]
• Time-frequency analysis to capture spectral features that correlate with motor intention or other cognitive states
• Machine learning classifiers including Support Vector Machines (SVM), Convolutional Neural Networks (CNN), and Long Short-Term Memory (LSTM) networks, which have been applied in 85% of recent lower-limb motor imagery studies [31]

These methods have demonstrated particular effectiveness for decoding motor imagery, especially when combined with multimodal fusion strategies that incorporate additional data streams, as employed in 65% of high-performance BCI systems [31].

Experimental Protocols and Validation

Preclinical Validation in Ovine Models

The development of endovascular BCIs has relied heavily on systematic preclinical validation using ovine models, which provide cerebral venous anatomy generalizable to humans [2]. Key experimental protocols include:

Surgical Implantation Procedure:

• Access: Percutaneous access via jugular vein
• Navigation: Catheter-based navigation to superior sagittal sinus under fluoroscopic guidance
• Deployment: Precise deployment of stent-electrode array adjacent to motor cortex regions
• Post-operative care: Anticoagulation regimen to prevent thrombosis during endothelialization

Neural Recording Protocol:

• Signal Acquisition: Chronic recording from electrode array over periods exceeding 12 months
• Behavioral Task: Sheep perform forced-choice tasks with movement constraints to isolate motor-related signals [3]
• Signal Validation: Comparison with simultaneous cortical recordings to validate signal fidelity
• Histological Analysis: Post-mortem examination of tissue integration and foreign body response

This approach has demonstrated that endovascular electrodes can acquire stable, high-quality motor-related brain signals sufficient to detect movement in forced-choice tasks with accuracy comparable to traditional invasive methods [3].

Clinical Translation in Human Trials

Early clinical trials have focused on patients with severe neurological conditions such as ALS, building upon the preclinical validation. The clinical protocol includes:

Patient Selection Criteria:

• Diagnosis of ALS or other conditions resulting in severe motor impairment
• Preserved cognitive function for task execution
• Anatomically suitable cerebral vasculature

Implantation and Recording Methodology:

• Pre-operative Planning: Venography to map venous anatomy and identify optimal stent placement
• Minimally Invasive Implantation: Endovascular delivery similar to preclinical procedure
• Signal Optimization: Adjustment of recording parameters post-endothelialization (typically 2-4 weeks post-implantation)
• Task Training: Patients practice motor imagery tasks to generate classifiable neural patterns
• Performance Validation: Quantitative assessment of communication accuracy or device control

Clinical results from six ALS patients demonstrated successful use of endovascular BCI for digital communication, establishing proof-of-concept for human application [2].

Regulatory and Data Considerations

The advancing field of neural interfaces is attracting appropriate regulatory scrutiny. The recently proposed MIND Act of 2025 would direct the Federal Trade Commission to study the collection, use, and safeguarding of neural data, recognizing brain signals as uniquely sensitive information [32] [33]. This proposed legislation aims to:

• Establish a regulatory framework for neural data that balances innovation with privacy protection
• Categorize neural data based on sensitivity with stricter oversight for high-risk applications
• Address potential risks including discrimination, profiling, surveillance, and manipulation
• Provide guidance for assessing harms when neural data is processed by AI systems [33]

For researchers, this evolving regulatory landscape underscores the importance of implementing robust data governance protocols, ensuring transparency in data processing, and developing secure data handling practices for neural information.

Endovascular stent-electrode arrays represent a promising minimally invasive approach for acquiring high-fidelity neural signals capable of driving brain-computer interfaces for communication and motor assistance. The signal acquisition and processing pipeline—from raw data collection through sophisticated machine learning-based decoding—has demonstrated sufficient performance to support real-world applications in severely paralyzed patients.

Future developments in this field will likely focus on optimizing electrode materials for enhanced biocompatibility and signal quality, refining endovascular procedures for precise targeting of specific functional regions, advancing signal processing algorithms through adaptive learning approaches, and establishing standardized protocols for clinical implementation. As the technology evolves, continued attention to ethical frameworks and regulatory standards will be essential for responsible translation of these powerful neural interfaces into clinical practice.

Application Notes: Current State of Digital Communication Restoration in ALS

The field of brain-computer interfaces (BCIs) has witnessed transformative advancements in restoring digital communication to patients with amyotrophic lateral sclerosis (ALS). These technologies translate neural activity into commands for communication, addressing the profound loss of speech and motor function that characterizes advanced ALS. Current research focuses on balancing high-fidelity signal acquisition with minimal surgical invasiveness, leading to several promising approaches.

Performance Metrics of Leading BCI Technologies

The table below summarizes the quantitative performance of key BCI technologies as demonstrated in recent human trials.

Table 1: Performance Metrics of BCI Technologies for Communication Restoration

Technology / Study	Interface Type	Primary Communication Output	Accuracy	Speed / Vocabulary	Key Advancement
UC Davis Speech BCI [34]	Intracortical Microelectrode Array	Text-to-Speech	97.5% word accuracy [34]	125,000-word vocabulary [34]	High-accuracy text decoding; personalized voice synthesis
UC Davis Real-Time Voice Synthesis [35]	Intracortical Microelectrode Array	Synthesized Voice	~60% word intelligibility [35]	Real-time, instantaneous synthesis [35]	Real-time vocal tract modeling; intonation control
Endovascular BCI (Stentrode) [2]	Stent-electrode Array (Venous)	Digital Control (Text)	Successful use for digital communication [2]	Not Specified	Minimally invasive access via blood vessels

Comparative Analysis of BCI Signal Acquisition Modalities

Different BCI approaches offer varying trade-offs between signal quality, invasiveness, and clinical applicability, as detailed below.

Table 2: Comparison of BCI Signal Acquisition Modalities

Feature	Endovascular BCI (Stentrode)	Intracortical Microelectrode Array	Thin-Film µECoG Array [16]
Surgical Invasiveness	Minimally invasive; via blood vessels [2]	Invasive; requires craniotomy [34]	Minimally invasive; "cranial micro-slit" technique [16]
Spatial Resolution	High; comparable to subdural arrays [2]	Very High; records individual neurons [34]	High; 400 µm inter-electrode pitch demonstrated [16]
Signal Quality	Stable long-term recordings [2]	High-fidelity; 97% speech decoding [34]	High-bandwidth; suitable for decoding [16]
Primary Clinical Benefit	Avoids open-brain surgery [2]	Highest reported accuracy for speech [34]	Scalable to >1000 channels; reversible [16]
Reported Human Trials	6 ALS patients [2]	Multiple participants (BrainGate trial) [34] [35]	Feasibility shown in 5 patients [16]

Experimental Protocols

This section provides detailed methodologies for key experiments and procedures in the development of communication-restoring BCIs.

Protocol: Implantation of an Endovascular Stent-Electrode Array

This protocol outlines the minimally invasive implantation of a stent-electrode array (e.g., Stentrode) within the superior sagittal sinus, based on established preclinical and clinical procedures [2].

• Objective: To achieve stable neural recording from the motor cortex via the venous system, avoiding the need for a craniotomy.
• Pre-operative Planning:
  • Conduct cerebral angiography via femoral venous access to map the venous vasculature and confirm anatomical suitability.
  • Identify the target region within the superior sagittal sinus adjacent to the precentral gyrus (primary motor cortex).
• Procedure:
  • Under fluoroscopic guidance, navigate a microcatheter delivery system from the femoral vein to the target region in the superior sagittal sinus.
  • Deploy the self-expanding stent-electrode array within the vessel, ensuring apposition against the venous wall for stable signal acquisition.
  • Confirm final device placement and patency of the vessel using fluoroscopy or computed tomography (CT).
  • Subcutaneously tunnel the lead from the venous access point to a pectoral region, where it is connected to a subcutaneous implantable telemetry unit.
• Post-operative Care:
  • Monitor for potential complications, including thrombosis or vessel injury.
  • Initiate anti-platelet therapy as per institutional protocol to mitigate thrombosis risk.
  • After recovery, initiate neural signal recording and calibration sessions.

Protocol: Intracortical BCI for Speech Decoding and Synthesis

This protocol details the surgical implantation and subsequent data collection for a speech neuroprosthesis, as utilized in the UC Davis Health clinical trials [34] [35].

• Objective: To record high-fidelity neural signals from the speech motor cortex for the purpose of decoding intended speech as text or synthesized voice.
• Surgical Implantation:
  • Perform a craniotomy to access the left precentral gyrus (a key region for speech motor coordination).
  • Implant four microelectrode arrays (e.g., Utah arrays), each containing 64 electrodes (256 channels total), into the cortical tissue.
  • Close the dura and secure the percutaneous connector to the skull.
• Data Acquisition & System Training:
  • Signal Recording: Record cortical activity from all electrodes while the participant attempts to speak or imagines speaking.
  • Prompted Speech Training: Present a set of words or sentences on a screen. Instruct the participant to attempt to say them aloud. Collect and align the neural data with the target phonemes and words.
  • Algorithm Training: Use machine learning models (e.g., recurrent neural networks) to map the neural activity patterns to the intended speech units (phonemes or words).
  • Voice Personalization: If synthesizing voice, use pre-existing audio samples of the participant's healthy voice to create a personalized digital voice [34].
• Real-Time Decoding & Testing:
  • The trained model translates neural signals into text or speech in real-time during attempted communication.
  • Performance is quantified via word error rate and intelligibility tests with naive listeners [35].

Protocol: Cranial Micro-Slit Implantation of High-Density µECoG Arrays

This protocol describes a minimally invasive technique for deploying high-density micro-electrocorticography (µECoG) arrays on the cortical surface, bridging the gap between invasiveness and signal resolution [16].

• Objective: To place a high-channel-count thin-film electrode array on the cortical surface without a full craniotomy.
• Procedure:
  • Trajectory Planning: Use CT or MRI guidance to plan a ~500-900 µm wide "micro-slit" incision in the skull, tangential to the cortical surface.
  • Micro-Slit Creation: Make the incision using a precision sagittal saw.
  • Array Insertion: Under endoscopic and/or fluoroscopic guidance, introduce the flexible, thin-film µECoG array through the slit and advance it subdurally over the target cortical region.
  • Placement Verification: Use endoscopy and intraoperative imaging to confirm the final position of the array.
  • Closure: Tunnel the array's cable subcutaneously and secure the external connector.
• Validation: The entire procedure can be completed in under 20 minutes per array. The feasibility of this protocol has been demonstrated in porcine models and human cadavers [16].

Visualization of Workflows and Signaling Pathways

BCI Signal Processing and Communication Workflow

Diagram 1: BCI signal processing workflow from neural activity to digital communication.

Endovascular BCI Implantation Pathway

Diagram 2: Endovascular BCI implantation and signal pathway.

The Scientist's Toolkit: Research Reagent Solutions

The following table catalogues essential materials and technologies used in the development of next-generation BCIs for communication restoration.

Table 3: Essential Research Materials and Technologies for BCI Development

Item Name / Category	Function / Application	Specific Examples / Notes
Stentrode Device	Endovascular neural recording electrode array [2].	Self-expanding stent platform with integrated electrodes; placed in cerebral venous sinus [2].
Microelectrode Arrays	High-density intracortical neural signal recording [34] [35].	Utah arrays; 256 channels implanted in speech motor cortex [34].
Thin-Film µECoG Arrays	High-density cortical surface recording via minimally invasive delivery [16].	1,024-channel arrays with 50 µm electrodes; deployed via cranial micro-slit [16].
Anti-Platelet Agents	Prevent thrombosis in endovascular implants [2].	e.g., Clopidogrel, Aspirin; critical for post-operative management of Stentrode [2].
Neural Signal Processor	Hardware for amplifying, filtering, and digitizing neural signals.	Custom headstages and application-specific integrated circuits (ASICs) [16].
Machine Learning Algorithms	Decode neural signals into intended speech or commands.	Recurrent Neural Networks (RNNs) for sequence modeling of speech [34] [35].
Digital Voice Bank	Creates a personalized synthesized voice for the user.	Trained on pre-morbid audio recordings of the patient [34].

Endovascular stent-electrode arrays (stentrodes) represent a transformative approach in neural interfacing, enabling chronic, high-fidelity recording of cortical neural activity without the need for open craniotomy [36] [11]. This minimally invasive platform involves the implantation of a passive stent-electrode recording array into superficial cortical veins overlying targeted brain regions via catheter angiography. The technology maintains venous patency while providing neural signal quality comparable to traditional epidural surface arrays, establishing a foundation for diverse clinical applications in neurological disorders [36]. This Application Note details specific protocols and evidence for stentrode implementation in epilepsy monitoring, motor control restoration, and neurorehabilitation, providing researchers with practical methodologies for translational development.

Application Note: Chronic Epilepsy Monitoring and Seizure Detection

Background and Rationale

Long-term seizure monitoring remains a critical challenge in epilepsy management, with approximately 70 million patients worldwide affected by this condition [37]. Traditional in-hospital video-EEG monitoring presents limitations in time, cost, and artificial environments that fail to capture authentic neurological activity in natural settings [38] [37]. Stentrode technology offers a novel solution for chronic, ambulatory monitoring of cortical activity, enabling detection of electrographic seizures and identification of seizure onset zones with reduced patient burden.

Performance Data and Validation

Table 1 summarizes key performance metrics for neural recording technologies in epilepsy applications.

Table 1: Performance Comparison of Neural Monitoring Technologies for Epilepsy

Technology	Spatial Resolution	Recording Duration	Seizure Detection Capability	Invasiveness
Stentrode Array [36] [11]	Comparable to ECoG	Up to 190 days (chronic)	Cortical seizure patterns	Minimally invasive (endovascular)
Bi-modal Wearable [38]	4-channel EEG + accelerometer	100+ hours (median)	1,609 seizures captured	Non-invasive (surface)
Traditional In-hospital VEEG [38] [37]	High (multi-channel)	3-7 days (limited)	Gold standard	Non-invasive but restrictive
µECoG Arrays [39]	57× higher than macro-ECoG	Intra-operative (acute)	Micro-scale epileptic signatures	Highly invasive (cortical surface)

Recent clinical evidence demonstrates the feasibility of long-term seizure monitoring using wearable technologies. A pilot study of a bi-modal wearable device recorded 3,724 hours of monitoring data, capturing 1,609 seizures across 14 epilepsy patients [38]. The device successfully identified various seizure types, including focal, focal with bilateral spread, and generalized/bilateral onset seizures. This demonstrates the potential for stentrode systems to provide similar long-term monitoring capabilities with the advantage of direct cortical recording without obscuration by the skull [38].

Experimental Protocol: Chronic Seizure Monitoring

Objective: To implement and validate stentrode-based chronic epilepsy monitoring in a preclinical model.

Materials:

• Stent-electrode array (passive, platinum-iridium electrodes)
• Angiographic catheter delivery system
• Biopotential acquisition system (wireless capable)
• Video monitoring system with time synchronization
• Seizure detection algorithm software

Procedure:

• Preoperative Planning:
  • Utilize MRV/CTV to identify a suitable superficial cortical vein overlying the epileptogenic zone (e.g., superior sagittal sinus or temporal lobe tributaries)
  • Create a 3D reconstruction of the venous anatomy using imaging software (e.g., 3D Slicer) [11]

• Stentrode Implantation:

  • Perform catheter angiography under general anesthesia
  • Navigate delivery catheter to target venous structure using fluoroscopic guidance
  • Deploy stent-electrode array to achieve wall apposition while maintaining venous patency
  • Confirm placement with fluoroscopy and impedance testing

• Neural Signal Acquisition:

  • Configure acquisition system for 0.5-300 Hz bandwidth with sampling rate ≥2 kHz [36]
  • Record continuous neural data with synchronized video monitoring
  • Implement wireless data transmission for ambulatory monitoring

• Seizure Detection and Analysis:

  • Apply bandpass filters (0.5-70 Hz for local field potentials; 70-150 Hz for high-gamma activity) [39]
  • Implement automated seizure detection algorithms based on spectral power changes
  • Correlate electrographic events with clinical manifestations via video review
  • Calculate seizure frequency, duration, and spatial distribution

Validation Metrics:

• Compare stentrode recordings with simultaneous surface EEG during monitored seizures
• Assess signal-to-noise ratio of interictal and ictal discharges
• Evaluate long-term signal stability over 180-day period
• Quantify seizure detection sensitivity and specificity against expert review

Application Note: Motor Control and Neuroprosthetics

Background and Rationale

High-fidelity neural recording enables decoding of motor intention for controlling external devices, offering potential restoration of function for patients with paralysis, ALS, or limb loss. Stentrodes placed in veins overlying motor cortex can capture movement-related neural signals while avoiding the inflammatory tissue responses associated with direct brain implantation [36] [11].

Performance Data and Validation

Table 2 summarizes neural decoding performance for motor control applications.

Table 2: Neural Decoding Performance for Motor Applications

Neural Interface	Spatial Resolution	Signal Quality	Decoding Accuracy	Application
Stentrode Array [36]	Comparable to ECoG	High-fidelity, broad spectrum	Demonstrated for motor cortex signals	Chronic motor decoding
µECoG Array [39]	1.33-1.72 mm inter-electrode	48% higher SNR than macro-ECoG	35% improvement over standard interfaces	Speech motor decoding
High-Density ECoG [39]	4 mm inter-electrode	Standard clinical quality	Phoneme prediction 5× lower than µECoG	Articulatory feature decoding
Macro ECoG [39]	10 mm inter-electrode	Lower spatial specificity	Limited fine motor decoding	Basic movement detection

Advanced decoding approaches leverage high gamma band (70-150 Hz) activity, which demonstrates high spatial specificity and correlation with multi-unit firing [39]. In speech decoding applications, µECoG arrays with high spatial resolution have demonstrated 35% improvement in decoding accuracy compared to standard intracranial signals, highlighting the importance of spatial resolution for complex motor decoding [39].

Experimental Protocol: Motor Intention Decoding

Objective: To decode motor intention from stentrode recordings for neuroprosthetic control.

Materials:

• Stentrode array in motor cortex region
• High-channel-count neural signal processor
• Movement tracking system (motion capture or EMG)
• Prosthetic device or computer interface
• Machine learning software platform (Python with scikit-learn or similar)

Procedure:

• Experimental Setup:
  • Implant stentrode in superior sagittal sinus or precentral vein overlying hand/arm motor area
  • Establish reliable neural recording with signal-to-noise ratio >5:1 for action potentials
  • Calibrate movement tracking system for kinematic recording

• Task Paradigm:

  • Implement center-out reaching task with visual cues
  • Record neural activity during attempted or actual movements
  • Vary movement direction, speed, and amplitude to sample parameter space
  • Include rest periods between movements to establish baseline

• Signal Processing:

  • Apply spatial filters to enhance signal quality
  • Extract time-frequency features with emphasis on high-gamma band (70-150 Hz)
  • Calculate firing rates for putative single units when detectable

• Decoder Training:

  • Align neural features with kinematic parameters (velocity, position)
  • Train linear (Wiener filter, Kalman filter) and non-linear (neural network) decoders
  • Validate model performance with cross-validation
  • Implement real-time decoding for closed-loop control

• Performance Assessment:

  • Quantify decoding accuracy using Pearson correlation coefficient and R² values
  • Assess information transfer rate for communication applications
  • Evaluate closed-loop control performance with Fitt's law paradigm

Validation Metrics:

• Movement trajectory reconstruction accuracy
• Target acquisition success rate and timing
• Bit rate for communication applications
• Long-term decoder stability over weeks to months

Application Note: Neurorehabilitation Monitoring

Background and Rationale

Wearable devices are increasingly utilized in neurological rehabilitation for objective assessment of motor recovery, particularly following stroke or traumatic brain injury [40]. Stentrodes enable direct recording of cortical reorganization during recovery, providing insights into neuroplasticity mechanisms and rehabilitation efficacy.

Performance Data and Validation

Table 3 summarizes wearable technology applications in neurorehabilitation.

Table 3: Wearable Technology for Neurorehabilitation Assessment

Technology	Parameters Measured	Clinical Application	Advantages	Limitations
Stentrode Array [36] [11]	Direct cortical signals	Neuroplasticity monitoring	High temporal resolution, chronic implantation	Invasive procedure
Dry EEG Headsets [37]	Brain activity patterns	Rehabilitation engagement	Quick setup (4.02 min), home use	Lower signal quality
Inertial Sensors [40]	Joint ROM, movement quality	Motor function assessment	Continuous monitoring, real-world environment	Indirect neural measure
fNIRS Systems [37]	Cortical blood flow	Brain activation mapping	Tolerant to movement	Lower temporal resolution

Complementary wearable technologies provide valuable context for stentrode applications. Inertial measurement units (IMUs) can track joint range of motion with high accuracy and repeatability [40], while dry electrode EEG systems reduce setup time to approximately 4 minutes compared to 6.36 minutes for wet electrode systems [37]. These technologies can be combined with stentrode recordings to correlate cortical activity with behavioral outcomes.

Experimental Protocol: Rehabilitation Progress Monitoring

Objective: To monitor neuroplastic changes during rehabilitation using stentrode recordings.

Materials:

• Stentrode array in targeted brain region
• Ambulatory neural data logger
• Wearable movement sensors (IMUs)
• Clinical assessment tools (Fugl-Meyer, ARAT, etc.)
• Data analysis platform with time-series capabilities

Procedure:

• Baseline Assessment:
  • Record resting-state neural activity pre-rehabilitation
  • Perform standardized clinical assessments of motor function
  • Record neural activity during attempted movements
  • Map cortical activation patterns for targeted functions

• Longitudinal Monitoring:

  • Schedule daily recording sessions during therapy activities
  • Synchronize neural recording with wearable sensor data
  • Document therapy type, intensity, and duration
  • Conduct weekly clinical assessments for correlation

• Signal Analysis:

  • Calculate laterality index of cortical activation
  • Track evolution of movement-related spectral changes
  • Identify aberrant oscillatory activity (e.g., excessive beta synchronization)
  • Assess functional connectivity between brain regions

• Outcome Correlation:

  • Relate neural metrics to clinical recovery trajectories
  • Identify neural biomarkers predictive of recovery plateaus
  • Detect maladaptive plasticity patterns early

Validation Metrics:

• Correlation between neural reorganization and functional improvement
• Sensitivity to detect recovery milestones before clinical manifestation
• Predictive value for long-term outcomes based on early neural changes
• Test-retest reliability of neural measures

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 4 provides key research reagents and materials for stentrode development and implementation.

Table 4: Essential Research Materials for Stentrode Applications

Item	Function	Specifications	Application Notes
LCP-TF µECoG Arrays [39]	High-resolution neural recording	1.33-1.72 mm inter-electrode distance, 200 µm exposed diameter	Reference standard for cortical recording quality
Platinum-Iridium Electrodes [36] [11]	Neural signal acquisition	Low impedance, high biocompatibility	Standard material for chronic implants
Angiographic Catheter System [36]	Stentrode delivery	Compatible with stentrode dimensions	Requires interventional neuroradiology expertise
Biopotential Acquisition System	Neural signal processing	0.5-3000 Hz bandwidth, ≥16-bit resolution	Wireless capability enables ambulatory monitoring
Impedance Testing Interface [39]	Electrode functionality verification	Measures 1-1000 kOhm range	Quality assurance pre/post-implantation
3D Reconstruction Software [11]	Venous anatomy mapping	Compatible with MRV/CTV data	Preoperative planning and targeting
High-Gamma Analysis Tools [39]	Neural feature extraction	70-150 Hz bandpass, Hilbert transform	Critical for motor decoding applications
Motion Tracking System	Kinematic recording	Sub-centimeter spatial accuracy	Ground truth for decoder training

Visualizing Experimental Workflows

Stentrode Implantation and Recording Setup

Neural Signal Processing Pipeline

Multi-Modal Neurorehabilitation Assessment

Addressing Technical Hurdles and Enhancing Performance

The development of endovascular stent-electrode arrays, such as the Stentrode, represents a paradigm shift in brain-computer interface (BCI) technology, offering a minimally invasive alternative to traditional cortical electrodes [2] [41]. These devices are deployed via the cerebral venous system to record neural signals from the motor cortex, eliminating the need for open craniotomy [42]. However, their permanent implantation within blood vessels introduces a significant challenge: the persistent risk of thrombosis. This application note details integrated strategies encompassing material biocompatibility and pharmacological anticoagulation to mitigate this risk, ensuring the safety and long-term functionality of endovascular neural interfaces.

Material Biocompatibility for Thrombosis Prevention

The fundamental principle governing material selection for endovascular electrodes is biocompatibility—the ability to perform with an appropriate host response in a specific application [43]. The ideal material minimizes immune activation and prevents the adsorption of plasma proteins that initiate the coagulation cascade.

Key Material Properties and Selection

The choice of material directly influences the thrombogenic response. Key properties include electrical conductivity, mechanical flexibility, and biostability [43].

Table 1: Material Properties for Endovascular Electrodes

Material Category	Example Materials	Key Properties	Impact on Thrombogenicity
Metals & Metal Alloys	Platinum-Iridium, Nitinol, Iridium Oxide [43] [42]	High electrical conductivity, radiopacity, excellent charge injection capacity (Iridium Oxide) [42]	Inert metals minimize ionic release; textured surfaces (e.g., platinum black) can increase protein adsorption if not optimized [43].
Conductive Polymers	PEDOT:PSS, Poly(pyrrole) (PPy) [43]	Lower impedance, mechanical softness, can deliver bioactive molecules [43]	Softer mechanics reduce chronic inflammation; polymer chemistry can be tailored to be protein-resistant.
Scaffold & Packaging	Polyimide, Parylene, Nitinol [43] [44]	Flexibility, biostability, hermetic sealing [44]	Smooth, stable surfaces prevent platelet adhesion and activation; flexibility minimizes vessel wall injury.

Material-Led Strategies to Reduce Thrombosis

• Surface Modification: Coatings such as iridium oxide are applied to electrode materials to enhance their electrochemical properties and improve biocompatibility. These coatings increase charge injection capacity, allowing for safer stimulation and more efficient recording, while also creating a more bioinert surface that is less likely to trigger coagulation or inflammatory responses [43] [42].
• Mechanical Compatibility: Device flexibility is critical. Stent-electrode arrays are often laser-cut from nitinol, a superelastic alloy that allows the device to conform to the curvature of the vessel wall without causing significant dilation or continuous mechanical irritation, thereby reducing the risk of endothelial injury that can initiate thrombosis [41] [42].
• Emerging Materials: Research into fully polymeric, transient neurovascular interfaces is underway. These devices use biodegradable polymer scaffolds and conductive polymers, which may reduce chronic inflammatory responses and the long-term risk of thrombosis associated with permanent metallic implants [41].

Anticoagulant Management Strategies

While material design minimizes the thrombogenic profile of the device, pharmacological anticoagulation is typically required to manage the acute and chronic thrombosis risk, especially in the high-flow, low-pressure environment of the venous sinuses.

Pre- and Peri-Operative Management

The goal during implantation is to balance the risk of procedure-related hemorrhage against the risk of device-related thrombosis. For elective procedures, anticoagulant medications such as vitamin K antagonists (VKAs, e.g., warfarin) or direct-acting anticoagulants (DOACs) are typically withheld prior to surgery [45]. The interruption time can be up to 5 days for DOACs in patients with normal renal function, though this must be individualized [45]. "Bridging therapy" with a short-acting anticoagulant like low molecular weight heparin is generally not recommended for high-bleed-risk surgeries like neurosurgical procedures.

Reversal Strategies in Emergency Settings

In cases where patients on therapeutic anticoagulation present with an acute neurosurgical event, such as a device-related hemorrhage, rapid reversal may be necessary. The strategy depends on the anticoagulant class [45].

Table 2: Anticoagulant Reversal Strategies in Neurosurgical Emergencies

Anticoagulant Class	Common Examples	Reversal Agent(s)	Clinical Application Notes
Vitamin K Antagonists (VKAs)	Warfarin	Vitamin K, Prothrombin Complex Concentrate (PCC), Fresh Frozen Plasma (FFP) [45]	PCC acts rapidly to replace clotting factors and is frequently/routinely used in combination with Vitamin K [45].
Direct-Acting Oral Anticoagulants (DOACs)	Dabigatran, Rivaroxaban, Apixaban	Specific reversal agents (e.g., Idarucizumab for Dabigatran), Activated PCC, Andexanet Alfa [45]	Specific reversal agents are preferred when available. In their absence, activated PCC may be used, though supporting evidence is less robust [45].

Long-Term Anticoagulation Regimen

Following the implantation of an endovascular device, a carefully considered long-term antithrombotic regimen is essential. Clinical trials of the Stentrode device have demonstrated safety with specific protocols. The SWITCH and COMMAND trials, which implanted the Stentrode in the superior sagittal sinus, utilized a dual antiplatelet therapy (DAPT) regimen, typically consisting of aspirin and clopidogrel, for a period of 1 to 3 months post-implantation [2] [42]. This was often followed by lifelong single antiplatelet therapy (usually aspirin) to prevent platelet aggregation and adhesion to the implanted device [42]. The choice between antiplatelet therapy and full anticoagulation depends on the patient's underlying thrombotic risk (e.g., pre-existing conditions like atrial fibrillation) and the specific location and design of the implanted device.

Experimental Protocols for Thrombosis Assessment

Rigorous preclinical testing is mandatory to evaluate the thrombogenic potential of new endovascular BCIs and optimize anticoagulation strategies.

In Vitro Hemocompatibility Testing

Protocol: Static Blood Clotting Assay

• Objective: To qualitatively assess the thrombogenicity of material surfaces.
• Methodology:
  • Prepare sterile discs of the test material (electrode or scaffold).
  • Place materials in a multi-well plate and add fresh, citrated human whole blood.
  • Add a calcium chloride solution to recalcify the blood and initiate the coagulation cascade.
  • Incubate at 37°C for a predetermined time (e.g., 60 minutes).
  • Carefully remove the clots and quantify them via spectrophotometric hemoglobin analysis.
  • Compare clot formation on test materials against positive (glass) and negative (polypropylene) controls.

In Vivo Preclinical Implantation Model

Protocol: Chronic Ovine Implantation for Safety and Efficacy

• Objective: To evaluate the long-term biocompatibility, thrombosis risk, and signal stability of a stent-electrode array [2].
• Methodology:
  • Animal Model: Adult sheep are commonly used due to the anatomical size and flow characteristics of their cerebral venous sinuses, which are comparable to humans [2].
  • Implantation: Under general anesthesia, the stent-electrode array is delivered via a transvenous femoral approach and deployed in the superior sagittal sinus under fluoroscopic guidance [2] [42].
  • Anticoagulation Regimen: Animals are placed on a dual antiplatelet regimen (e.g., aspirin and clopidogrel) for the initial 1-3 months, mirroring the clinical protocol [42].
  • Monitoring:
    • Clinical: Daily observation for neurological deficits.
    • Radiological: Periodic angiography or MRI to assess vessel patency and rule out thrombus formation.
    • Signal Fidelity: Continuous recording of neural signal quality and signal-to-noise ratio over the implant duration (e.g., 190 days) [2].
  • Terminal Histology: Upon study completion, the brain and underlying vessels are perfused-fixed and explanted. Histological analysis (H&E stain, Masson's Trichrome) is performed to evaluate endothelialization, intimal hyperplasia, inflammation (presence of glial cells, macrophages), and any evidence of thrombus formation [2] [44].

Diagram 1: Preclinical thrombosis risk assessment workflow.

The Scientist's Toolkit: Essential Reagents & Materials

Table 3: Key Research Reagents and Materials for Thrombosis Mitigation R&D

Item Name	Function/Application	Example Usage
Platinum-Iridium Alloy	Primary electrode material due to its high conductivity, radiopacity, and biocompatibility.	Fabrication of recording and stimulating electrodes on stent arrays [43] [42].
Iridium Oxide Coating	Electrode coating to enhance charge injection capacity and improve chronic stability.	Applied to platinum-iridium electrodes to lower impedance and improve signal-to-noise ratio for long-term implants [43] [42].
Nitinol Scaffold	A superelastic shape-memory alloy used for the self-expanding stent structure.	Provides the structural backbone for the Stentrode, allowing for compact delivery and stable expansion within the vessel [41] [42].
Dual Antiplatelet Therapy (DAPT)	Standard pharmacological regimen to prevent acute stent thrombosis.	Administration of Aspirin and Clopidogrel for 1-3 months post-implantation in preclinical and clinical studies [42].
Prothrombin Complex Concentrate (PCC)	Reversal agent for Vitamin K Antagonist (VKA) anticoagulation in emergency settings.	Used for rapid reversal of warfarin in cases of serious bleeding, as reported in neurosurgical practice surveys [45].
Specific DOAC Reversal Agents	Targeted reversal for Direct-Acting Oral Anticoagulants.	Idarucizumab for Dabigatran or Andexanet Alfa for Factor Xa inhibitors, used in emergency bleeding scenarios [45].

For researchers developing endovascular stent-electrode arrays, achieving long-term signal stability is a paramount challenge that directly influences the clinical viability of these minimally invasive brain-computer interfaces (BCIs). These devices, implanted within the cerebral venous system, offer significant advantages by avoiding open brain surgery but face unique stability challenges from the biological milieu [2]. This document provides application notes and experimental protocols designed to quantify, monitor, and mitigate electrode degradation and signal drift, based on current research and analysis of chronically implanted neural interfaces.

Quantitative Stability Metrics from Recent Studies

Understanding the typical performance metrics of chronically implanted devices is crucial for setting experimental benchmarks and evaluating the success of stability strategies. The following table summarizes key quantitative findings from recent clinical and preclinical studies on various neural electrode arrays.

Table 1: Performance and Degradation Metrics of Chronically Implanted Electrode Arrays

Array Type / Study	Implantation Duration	Key Stability Metrics	Degradation Observations
Endovascular (Stentrode) [46]	Up to 12 months (Human)	Sustained motor modulation in high-frequency bands (30-200 Hz); Stable electrode impedance and resting-state band power over time.	Study reported stable signal characteristics suitable for long-term neural signal acquisition in a home environment.
Utah Array (Pt & SIROF) [47]	956 - 2,246 days (Human)	SIROF electrodes were twice as likely to record neural activity (measured by SNR) than Pt electrodes at explant.	1 kHz impedance correlated with physical damage metrics for SIROF. "Pockmarked" degradation on stimulated electrodes. Erosion of silicon shank often precedes tip metal damage.
Micro-ECoG Array [16]	42 days (Chronic, Preclinical)	>93% electrode yield pre-insertion; Minimal change in electrode impedance ratio pre/post-implantation.	Formal safety studies showed minimal tissue reactivity compared to controls, supporting the reversibility and safety of the implantation method.

Experimental Protocols for Assessing Electrode Stability

To ensure the collection of high-quality, comparable longitudinal data, researchers should adhere to the following standardized protocols.

Protocol for Chronic In Vivo Signal Recording and Analysis

This protocol is designed for the longitudinal assessment of endovascular BCI performance in a clinical or preclinical setting [46].

Aim: To quantitatively track the stability of neural signals and electrode performance over multi-month periods. Materials:

• Implanted endovascular stent-electrode array (e.g., Stentrode).
• Neural signal acquisition system.
• Computational setup for signal processing and analysis.

Method:

• Home-Based Recording Sessions: Conduct regular recording sessions in the participant's home environment to collect data under real-world conditions.
• Standardized Task Paradigm:
  • Instruct the participant to perform attempted movements (e.g., ankle movement) cued by a visual or auditory stimulus.
  • Record neural activity during these tasks, ensuring consistent trial structure (e.g., 2-second rest period before the "go" cue).
• Data Processing and Metric Calculation:
  • Signal Modulation Strength: Calculate the z-scored power in relevant frequency bands (e.g., low and high gamma, 30-200 Hz) during the movement attempt epoch compared to the rest epoch.
  • Impedance Tracking: Measure electrode impedance across all channels at regular intervals (e.g., weekly).
  • Resting-State Power: Quantify features of the signal power spectral density (PSD) during rest periods.

Protocol for Post-Explant Electrode Degradation Analysis

This methodology details the quantitative assessment of physical degradation in explanted microelectrode arrays, providing a direct link between abiotic damage and functional outcomes [47].

Aim: To systematically quantify physical damage on explanted electrodes and correlate it with in vivo functional data. Materials:

• Explanted microelectrode arrays (e.g., Neuroport arrays).
• Scanning Electron Microscope (SEM).
• Expert panel for image rating.

Method:

• Sample Preparation: Clean and prepare explanted arrays for SEM imaging.
• Imaging: Capture high-resolution SEM images of all electrode tips.
• Expert Rating: Have human experts rate each electrode based on five key damage metrics using a standardized scale:
  • Loss of Tip Metal: Quantifying the erosion of the conductive material.
  • Electrode-Tissue Separation: Assessing the gap between the silicon shank and the tip metal.
  • Tissue/Bio-material Adherence: Measuring the extent of biological material on the electrode.
  • Shank Insulation Damage: Evaluating cracks or wear in the insulating layer (e.g., Parylene-C).
  • Silicone Shaft Damage: Inspecting the structural integrity of the shaft.
• Data Correlation: Statistically compare the physical damage scores with longitudinal functional data collected prior to explant, including:
  • Signal-to-Noise Ratio (SNR)
  • In vivo impedance measurements
  • Stimulation performance records

The Scientist's Toolkit: Essential Research Reagents and Materials

Selecting the appropriate materials is critical for optimizing the longevity and performance of neural interfaces. The table below catalogs key materials and their functions, informed by performance comparisons in chronic implants.

Table 2: Key Materials for Neural Electrodes and Their Functional Impact

Material / Reagent	Function / Application	Impact on Long-Term Stability & Notes
Sputtered Iridium Oxide Film (SIROF)	Electrode coating material for recording and stimulation.	Demonstrates superior functional longevity. Shown to be twice as likely to record neural activity than Platinum at explant, despite higher physical degradation levels [47].
Platinum (Pt)	Traditional electrode tip metal for recording.	Prone to higher failure rates over the long term compared to advanced coatings like SIROF [47].
Parylene-C	Biocompatible polymer used as insulation for electrode shanks.	Subject to cracking under physiological conditions over time, which can lead to decreased impedance and functional failure [47].
Carbon Fiber Electrodes	Ultrafine (6.8–8.4 µm), minimally penetrating electrodes for "neural dust" motes.	High strength at small sizes enables reliable insertion. Subcellular scale reduces bending stiffness, potentially minimizing foreign body response and improving biocompatibility [48].
Polyethylene Glycol (PEG)	Biocompatible, quickly dissolvable material used as a temporary adhesive for batch implantation.	Enables rapid, simultaneous implantation of multiple electrode motes with high success rates (92%), facilitating scalable deployment [48].

Visualization of Workflows and Relationships

The following diagrams outline core experimental and analytical processes for stability research, created using the specified color palette with high-contrast text.

Diagram 1: Long-Term Stability Assessment Workflow

Diagram 2: Electrode Degradation Metrics & Impact

Endovascular stent-electrode arrays represent a transformative approach in neural interface technology, enabling minimally invasive recording of brain activity via the cerebral venous system. Unlike traditional invasive brain-computer interfaces (BCIs) that require open-brain surgery, these devices are delivered through blood vessels, significantly reducing tissue damage and surgical risk [2]. The fundamental operating principle involves deploying an electrode-studded stent within veins adjacent to neural tissue, allowing recording of electrophysiological signals without direct brain penetration. This approach has demonstrated stable long-term neural recording capabilities in both ovine models and human clinical trials involving patients with amyotrophic lateral sclerosis (ALS) [2].

The Stentrode device has emerged as a prominent example of this technology, featuring electrode arrays integrated onto self-expanding stent structures. Preclinical studies in ovine models have established the viability of this approach, demonstrating that endovascular electrodes can achieve signal quality rivaling traditional subdural arrays while maintaining excellent safety profiles [2]. In human trials, six ALS patients successfully utilized this technology for digital communication, highlighting its clinical potential [2]. Despite these promising results, optimizing signal quality remains a significant focus of ongoing research, with particular emphasis on electrode design, materials science, and noise reduction strategies to enhance the fidelity of neural recordings.

Electrode Design Principles for Neural Interfaces

Material Selection and Biocompatibility

Electrode material selection critically influences signal quality, biocompatibility, and long-term stability in neural interfaces. Materials must exhibit optimal electrical properties while maintaining compatibility with the biological environment. Recent clinical evidence from long-term human implantation studies demonstrates that sputtered iridium oxide film (SIROF) electrodes significantly outperform platinum (Pt) in chronic recording applications. A comprehensive analysis of 980 microelectrodes explained from three human participants after 956-2130 days of implantation revealed that SIROF electrodes were twice as likely to record neural activity than Pt, as measured by signal-to-noise ratio (SNR) [49].

Table 1: Electrode Material Performance in Chronic Human Implants

Material	Recording Likelihood	Signal-to-Noise Ratio	Degradation Resistance	Impedance Stability
SIROF	2× higher than Pt	Superior	Moderate	Correlates with performance metrics
Platinum (Pt)	Baseline	Lower	Higher physical degradation	Less correlated with function

Material degradation presents a significant challenge for long-term neural interfaces. Scanning electron microscopy analysis of explanted electrodes revealed two primary degradation patterns: "pockmarked" surfaces, primarily observed on stimulated electrodes, and "cracked" electrodes [49]. These physical changes directly impact electrical performance, with 1 kHz impedance significantly correlating with all physical damage metrics, recording quality, and stimulation performance in SIROF electrodes [49]. Researchers hypothesize that penetration of the electrode tip by biotic processes leads to erosion of the supporting silicon core, which then accelerates further tip metal damage—a critical consideration for future material development.

Structural Design and Configuration

Electrode structural design significantly influences signal quality through multiple mechanisms. Innovative hollow electrode designs on quartz substrates have demonstrated remarkable improvements in signal quality, reducing equivalent capacitance from 40 pF to 30 pF while enhancing the quality factor by nearly 120 times compared to full-electrode configurations [50]. This reduction in capacitance directly decreases dielectric loss noise, a major contributor to overall system noise.

Three-dimensional electrode configurations and surface topography modifications further enhance recording performance. Increased surface area-to-volume ratios improve electrical characteristics while maintaining minimal physical footprints. Advanced manufacturing techniques enable complex geometries that optimize the electrode-electrolyte interface, enhancing charge transfer efficiency and reducing interfacial impedance [50]. For endovascular applications, the mechanical properties of electrode arrays must complement these electrical optimizations, incorporating flexibility to accommodate vascular dynamics and ensure stable positioning against vessel walls.

Noise Reduction Strategies in Neural Recording Systems

Effective noise reduction begins with comprehensive characterization of noise sources in neural recording systems. Three primary noise categories dominate electrophysiological recordings: dielectric loss noise arising from the electrode-tissue interface and substrate materials; DC resistance noise associated with conductor pathways; and charge amplifier noise originating from front-end electronics [50]. The relative contribution of each noise source varies depending on electrode design, material properties, and recording configuration.

In endovascular applications, additional noise considerations include biological and environmental factors. Vasculature dynamics, blood flow, and cardiac pulsatility introduce low-frequency noise components, while environmental electromagnetic interference can affect higher frequencies. Understanding these noise characteristics enables targeted reduction strategies at both the electrode design and signal processing levels. Recent advances in magnetoelectric sensor technology have demonstrated equivalent magnetic noise levels below 6.10 pT/Hz¹/² across frequency ranges from 20 kHz to 50 kHz, with detection limits as low as 10 fT at resonance [50].

Advanced Materials and Processing for Noise Reduction

Material processing techniques significantly influence noise characteristics in neural recording systems. Magnetic annealing of magnetostrictive materials like Metglas (FeCoSiB) enhances soft magnetic properties, reducing magnetic losses and associated noise [50]. This thermal processing facilitates a transition from amorphous to nanocrystalline states, yielding higher initial magnetic permeability, enhanced saturation magnetization, and lower magnetic loss—all contributing to improved signal fidelity.

Table 2: Noise Reduction Techniques and Performance Metrics

Technique	Principle	Noise Reduction	Application
Hollow Electrode Design	Reduced equivalent capacitance	122.83× quality factor improvement	Piezoelectric layers
Magnetic Annealing	Enhanced soft magnetic properties	0.78× background noise decrease	Magnetostrictive layers
Lead-Free Piezoelectrics	Reduced dielectric loss	Equivalent magnetic noise <6.10 pT/√Hz	Magnetic field sensing
SIROF Electrodes	Superior charge transfer	2× SNR improvement vs. Pt	Chronic implantation

The development of lead-free piezoelectric materials represents another significant advancement in noise reduction. While lead-based single crystals like PMN-PT and PZN-PT offer superior piezoelectric coefficients, environmental concerns and high costs have driven research into alternatives [50]. Quartz single crystals demonstrate exceptional performance as piezoelectric phases in magnetoelectric composites, offering high Q-factor characteristics that enable sensitive magnetic field detection with resolutions of 8 mOe [50]. These materials provide excellent voltage coefficients (d/ε) while minimizing parasitic capacitance, making them particularly suitable for low-noise neural recording applications.

Experimental Protocols for Electrode Characterization

Protocol for Assessing Electrode-Tissue Interface Stability

Objective: Systematically evaluate the stability and performance of endovascular electrode-tissue interfaces during chronic implantation.

Materials:

• Stent-electrode arrays (SIROF or Pt electrode options)
• Electrochemical impedance spectroscopy (EIS) measurement system
• Custom signal recording setup with programmable gain amplifiers
• Scanning electron microscope for post-explant analysis
• Animal model (ovine) or human clinical participants

Procedure:

• Pre-implantation Characterization: Measure baseline electrode impedance at 1 kHz using EIS. Characterize noise floor and signal-to-noise ratio using standardized test signals.
• Surgical Implantation: Deploy stent-electrode array via endovascular access to target venous structure under fluoroscopic guidance.
• Chronic Monitoring: Record neural signals regularly (daily for first month, then weekly). Document signal amplitude, noise characteristics, and viable channel count.
• Impedance Tracking: Perform biweekly EIS measurements across frequency spectrum (10 Hz - 10 kHz) to monitor interface changes.
• Functional Assessment: Quantify ability to record task-related neural signals and decode intended movements or commands.
• Post-explant Analysis: Following explanation, examine electrodes using SEM to quantify physical degradation. Correlate degradation metrics with functional performance.

Analysis: Calculate correlation coefficients between physical degradation metrics (pitting, cracking, delamination) and electrical performance parameters (impedance, noise floor, SNR). Compare SIROF versus Pt electrodes using two-sample t-tests with significance level p < 0.05.

This protocol was employed in a comprehensive study analyzing 980 electrodes from eleven Neuroport arrays, revealing significant correlations between material properties, physical degradation, and functional outcomes [49].

Protocol for Evaluating Noise Reduction Techniques

Objective: Quantitatively compare the efficacy of different electrode designs and materials for reducing equivalent magnetic noise.

Materials:

• Magnetoelectric sensor test platform
• Electrode configurations (hollow, full, patterned designs)
• Metglas samples (annealed and non-annealed)
• Quartz/Metglas magnetoelectric composites
• Network analyzer for impedance measurements
• Shielded test chamber

Procedure:

• Sample Preparation: Fabricate electrodes with hollow and full designs on quartz substrates. Prepare Metglas samples with and without magnetic annealing.
• Baseline Measurement: Characterize initial equivalent capacitance and quality factor for each electrode configuration.
• Noise Characterization: Measure equivalent magnetic noise across frequency spectrum (1 Hz - 50 kHz) in shielded environment.
• ME Coefficient Determination: Apply calibrated magnetic fields and measure voltage output to calculate magnetoelectric coefficient.
• Limit of Detection Assessment: Determine minimum detectable magnetic field for each configuration.
• Accelerated Aging: Subject samples to simulated physiological conditions while monitoring noise performance.

Analysis: Compare quality factor improvements, equivalent magnetic noise reduction, and detection limit enhancements across configurations. Calculate percentage improvement for optimized designs relative to baseline.

This methodological approach enabled researchers to demonstrate that optimized quartz/Metglas composites can achieve ME coefficients of 81.34 V/Oe with detection limits of 10 fT at resonance [50].

Research Reagent Solutions for Endovascular Neural Interfaces

Table 3: Essential Research Materials for Endovascular BCI Development

Material/Reagent	Function	Application Example	Performance Considerations
Sputtered Iridium Oxide Film (SIROF)	Electrode coating	Chronic neural recording	2× recording likelihood vs. Pt; stable charge transfer
Metglas 1K101	Magnetostrictive layer	Magnetic field sensing	Requires magnetic annealing; low coercive field, high permeability
X-cut Quartz Crystal	Piezoelectric substrate	Low-noise signal acquisition	High Q-factor; low equivalent capacitance
Platinum-Iridium Alloys	Electrode material	Conventional neural interfaces	Higher degradation vs. SIROF; established biocompatibility
Flexible Polymer Substrates	Electrode support	Conformable vascular interfaces	Balance of flexibility and durability; long-term stability

Signaling Pathways and Experimental Workflows

Neural Signal Acquisition and Processing Pathway

The following diagram illustrates the complete pathway from neural signal generation to processed output in endovascular recording systems:

Electrode Optimization Experimental Workflow

The diagram below outlines the systematic workflow for evaluating and optimizing electrode designs for neural recording applications:

Optimizing signal quality in endovascular stent-electrode arrays requires a multidisciplinary approach integrating materials science, electrode design, noise reduction strategies, and sophisticated signal processing. The development of advanced materials like SIROF has demonstrated significant improvements in chronic recording performance, while innovative electrode configurations and processing techniques have enabled substantial noise reduction. Experimental protocols must rigorously characterize both initial performance and long-term stability to ensure clinical viability.

Future research directions should focus on enhancing electrode biocompatibility and longevity, developing increasingly sophisticated noise cancellation algorithms tailored to the unique endovascular environment, and optimizing signal processing pipelines for real-time operation. As these technologies mature, endovascular neural interfaces hold tremendous promise for restoring communication and control for individuals with severe neurological impairments, offering a minimally invasive alternative to traditional cortical recording approaches with comparable signal fidelity and improved safety profiles.

Endovascular stent-electrode arrays, such as the Stentrode, represent a paradigm shift in brain-computer interface (BCI) technology by enabling chronic neural recording and stimulation from within the cerebral vasculature [2] [14]. This minimally invasive approach leverages the blood vessels as a natural pathway to access eloquent cortical regions, thereby eliminating the need for open-brain surgery and reducing the risk of tissue damage and chronic inflammation associated with traditional intracortical implants [3] [14]. A critical challenge for endovascular neural interfaces, particularly for electrical stimulation, has been the limited charge injection capacity (CIC) of conventional electrode materials, which can lead to high current requirements, electrode degradation, and ineffective neural activation [6] [51].

Platinum (Pt) is a cornerstone material for neural stimulation electrodes due to its high biocompatibility and excellent electrical conductivity. However, smooth platinum electrodes have a relatively low effective surface area, which constrains their CIC and can lead to dissolution under aggressive electrical stimulation regimes [51]. Platinum black coatings, created by electrodeposition or sputter coating, address this limitation by creating a nanostructured, highly porous surface that drastically increases the electroactive area [6] [52]. This nanoscale roughening enhances key electrochemical properties, enabling safer and more efficacious stimulation of neural tissue from an endovascular location, thereby opening new possibilities for minimally invasive neuromodulation therapies [6].

Performance and Characterization Data

The enhancement of electrochemical performance through platinum black coatings is quantifiable across several key metrics. The following tables summarize comparative data between uncoated platinum and platinum black-modified electrodes, crucial for evaluating their suitability for endovascular neural stimulation.

Table 1: Electrochemical Performance Comparison of Uncoated Platinum vs. Platinum Black Electrodes

Performance Parameter	Uncoated Platinum	Platinum Black Coated	Measurement Context
Charge Injection Capacity (CIC)	21.9 µC cm⁻²	64.9 µC cm⁻²	Maximum safe charge injection limit derived from voltage transients [6]
Charge Storage Capacity (CSCc - Cathodic)	Substantially lower	Substantially higher	Calculated from cyclic voltammetry (CV) cathodic sweep [6]
Total Impedance at 10 Hz	Higher	Significantly reduced	Measured via Electrochemical Impedance Spectroscopy (EIS) [6]
Polarization Voltage (Ep)	Higher for a given charge	Reduced for a given charge	Measured during chronopotentiometric voltage transients [6]
Electrochemical Stability	Shows degradation	More stable post-stimulation	Following a 7-day continuous stimulation protocol [6]

Table 2: Impact of Platinum Black on Endovascular Stimulation Efficacy

Parameter	Impact of Platinum Black Coating	Significance for Endovascular Interfaces
Stimulation Safety Window	Widens the safe window for stimulation	Reduces risk of tissue damage or electrode dissolution during stimulation [6] [51]
Electrode-Neuron Distance	Substantially increases the effective stimulation range	Allows effective stimulation through the blood vessel wall to target neural tissue [6]
Signal-to-Noise Ratio (SNR)	Improved for recording applications	Enhanced surface area reduces impedance, leading to higher fidelity neural recordings [52] [53]
Long-Term Biostability	Promotes stable interface post-endothelialization	The coating's stability supports chronic device functionality as the stent becomes incorporated into the vessel wall [6] [14]

Experimental Protocols for Evaluation

To ensure the reliability and efficacy of platinum black coatings for endovascular applications, a standardized set of characterization protocols is essential. The following sections detail critical methodologies for fabrication, electrochemical testing, and stability assessment.

Platinum Black Deposition via Electrodeposition

Objective: To create a uniform, nanoporous platinum black coating on a platinum electrode surface to enhance its effective surface area.

• Reagents: Chloroplatinic acid solution, Lead(II) nitrate (optional, see note), Formic acid (as an alternative electrolyte), or High-purity platinum sputter target [6] [52].
• Equipment: Potentiostat/Galvanostat, Standard three-electrode electrochemical cell (working, counter, and reference electrodes).
• Procedure:
  • Surface Preparation: Clean the smooth platinum working electrode thoroughly with solvents and oxygen plasma to ensure a pristine surface for deposition [52].
  • Electrolyte Preparation: Prepare an electrolyte solution, for example, containing chloroplatinic acid. Note: Lead acetate has been used historically as an additive to control deposition morphology, but cytotoxicity concerns encourage the use of additive-free formulations [52].
  • Deposition: Immerse the electrode and apply a constant potential or current. For instance, chronoamperometric deposition at -0.4 V vs. a Ag/AgCl reference electrode can yield a uniform, nanoporous layer with minimal edge effects [52].
  • Rinsing and Storage: Gently rinse the coated electrode with deionized water to remove electrolyte residues and store in a clean environment.

Technical Note: Sputter coating at high pressures is an alternative, dry fabrication method that can produce platinum black without the need for liquid electrolytes, potentially offering easier integration into manufacturing workflows [6].

Electrochemical Characterization

Objective: To quantitatively evaluate the key performance metrics of the coated electrode, including charge injection capacity, impedance, and charge storage.

• Reagents: 0.9% saline solution (non-degassed, to mimic the ionic composition and oxygen tension of the vascular environment) [6].
• Equipment: Potentiostat, Three-electrode setup.
• Procedures:
  • A. Cyclic Voltammetry (CV):
    • Run CV at a scan rate of 50 mV s⁻¹ over a potential window of -0.6 V to 0.8 V vs. Ag/AgCl [6].
    • Calculate the anodic and cathodic charge storage capacity (CSC) by integrating the current in the respective sweeps of the first cycle. This provides a direct measure of the charge available at the electrode interface [6].
  • B. Electrochemical Impedance Spectroscopy (EIS):
    • Perform EIS at 0 V with a 10 mV amplitude across a frequency range of 1 Hz to 200 kHz [6].
    • Analyze the impedance magnitude and phase to understand the interfacial properties, with a key focus on the low-frequency impedance (e.g., at 10 Hz) which is critical for neural stimulation efficacy [6].
  • C. Chronopotentiometric Voltage Transients (VT):
    • Apply a cathodic-first, biphasic current pulse with a 250 µs phase width and varying amplitudes [6].
    • Measure the access voltage (Ea) and polarization voltage (Ep). The maximum charge injection capacity (CIC) is determined as the charge density at which Ep reaches the water reduction limit (e.g., -600 mV), which can be found via extrapolation from a plot of Ep vs. charge density [6].

Chronic Stability Assessment

Objective: To evaluate the mechanical and electrochemical stability of the platinum black coating under continuous operation, simulating long-term implantation.

• Equipment: Programmable electrical stimulator.
• Procedure:
  • Accelerated Aging: Subject multiple coated electrodes to continuous biphasic pulsed stimulation in saline at 37°C for a minimum of 7 days. The stimulation amplitude should be set to a significant percentage (e.g., 90%) of the previously measured CIC [6].
  • Post-Stimulation Analysis:
    • Re-characterization: Repeat the electrochemical characterization (CV, EIS, VT) to quantify any degradation in performance [6].
    • Physical Inspection: Use helium ion microscopy (HIM) or scanning electron microscopy (SEM) to examine the coating for signs of delamination, cracking, or erosion [6] [52].
    • Material Analysis: Employ techniques like X-ray photoelectron spectroscopy (XPS) to check for changes in surface chemistry and inductively coupled plasma mass spectrometry (ICP-MS) to detect platinum dissolution into the saline medium [51].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Key Reagents and Materials for Developing Platinum Black Endovascular Electrodes

Item	Function/Application	Technical Notes
Nitinol Stent Scaffold	Mechanical backbone for the endovascular array; provides self-expanding property for stable deployment in blood vessels.	Biocompatible alloy with superelasticity; must be electropolished for biocompatibility [6] [14].
Polyimide Substrate	Flexible, biocompatible dielectric film for patterning thin-film electrode arrays.	Serves as an insulating substrate for conductive traces; enables integration with the stent scaffold [14].
Chloroplatinic Acid (H₂PtCl₆)	Precursor salt for electrodeposition of platinum black coatings.	Used in electrolyte baths for electrochemical deposition; concentration and additives control deposit morphology [52].
Phosphate Buffered Saline (PBS)	Standard electrolyte for in vitro biocompatibility and initial electrochemical testing.	Note: Phosphate ions can adsorb to platinum and alter electrochemistry; 0.9% saline may be a better model for in vivo conditions [6].
Parylene-C	Biostable polymer used as a conformal insulating coating for microelectrodes and conductive traces.	Provides a flexible, moisture-resistant barrier that prevents electrical shorts and protects the underlying electronics [14].
Iridium Oxide	Alternative high-performance coating material with very high charge injection capacity.	Can be used alone or in conjunction with platinum; applied via sputtering or electrochemical activation [14].

Workflow and Signaling Pathways

The following diagram illustrates the logical workflow for the development, characterization, and application of platinum black-coated endovascular electrodes, from material fabrication to in vivo efficacy assessment.

Electrode Development Workflow

The conceptual signaling pathway of an endovascular electrode stimulating a neuron through the vessel wall is summarized below, highlighting the key stages from electrical pulse to neural activation.

Neural Stimulation Pathway

Application Notes

The successful deployment of endovascular stent-electrode arrays for neural recording research is critically dependent on robust protocols for patient selection and preoperative planning. These initial stages are paramount for mitigating the risks associated with anatomical variability and ensuring high-quality electrophysiological data acquisition. This document outlines the essential procedures and considerations for navigating this complex landscape, framed within the context of advancing minimally invasive neural recording research.

The core challenge lies in aligning the technical specifications of the stent-electrode array with the unique neurovasculature of each research subject. A meticulous, multi-modal planning process is essential to confirm that target vessels are anatomically suitable for device placement and are positioned to yield optimal neural signals from regions of interest. Furthermore, a comprehensive safety assessment must identify any vascular pathologies or anatomical constraints that could elevate procedural risk. The following protocols provide a standardized framework for achieving these objectives, incorporating quantitative data and detailed methodologies to enhance reproducibility and safety in preclinical and clinical research settings.

Quantitative Data for Preoperative Assessment

The following tables summarize key quantitative parameters essential for patient selection and preoperative planning.

Table 1: Preoperative Imaging and Vascular Anatomy Assessment Criteria

Assessment Parameter	Target Value / Acceptable Range	Clinical/Research Significance	Primary Imaging Modality
Target Vessel Diameter	Sufficient to accommodate stent-electrode deployment [54]	Ensures stable apposition and minimizes risk of vessel injury or occlusion [55]	MRV, CTA, DSA [55]
Vessel Tortuosity	Minimal to moderate; absence of acute angulation proximal to target site	Facilitates safe and navigable device delivery [55]	MRA, CTA, DSA [55]
Cortical Proximity	Vessel in close proximity to cortical surface (e.g., Superior Sagittal Sinus, Transverse Sinus) [54]	Maximizes amplitude of recorded neural signals (e.g., up to 200 μV) [54]	MRI with venous mapping [54]
Presence of Pathology	Absence of stenosis, dissection, or significant thrombosis [55]	Reduces risk of thromboembolic or hemorrhagic complications [55]	DSA (gold standard), CTA, MRA [55]

Table 2: Technical Specifications of a Representative Stent-Electrode Array and Recorded Signals

Feature	Specification	Implication for Planning
Electrode Count	32-channel system cited [54]	Determines spatial resolution and coverage of neural recording.
Recorded Signal Amplitude	Up to 200 μV from visual cortex [54]	Informs signal processing and amplification requirements.
Induced Activity	Seizure-like spikes observed with Pentetrozol [54]	Provides a method for validating device functionality in preclinical models.
Lead Configuration	Transvascular lead to external acquisition system [54]	Requires planning for lead routing and externalization.

Experimental Protocols

Protocol for Preoperative Imaging and 3D Vascular Reconstruction

This protocol details the steps for acquiring and processing imaging data to create a patient-specific 3D model for procedural planning [54].

I. Materials and Equipment

• Magnetic Resonance Imaging (MRI) system with contrast capability.
• MRI-compatible contrast agent.
• 3D image processing workstation with segmentation software (e.g., 3D Slicer, Mimics).
• Computed Tomography Angiography (CTA) or Digital Subtraction Angiography (DSA) suite, if required [55].

II. Procedure

• Subject Preparation: Place the subject under general anesthesia. Administer a paramagnetic contrast agent intravenously to enhance venous vasculature visibility during MRI [54].
• Image Acquisition: Perform an MRI scan with a protocol optimized for high-resolution venous vascular enhancement. Key sequences should include T1-weighted 3D gradient-echo post-contrast (e.g., MRV).
• Image Segmentation and 3D Reconstruction: Transfer the acquired DICOM images to the 3D processing workstation.
  • Use intensity thresholding and region-growing algorithms to isolate the dural venous sinuses and other target vessels from surrounding brain tissue and bone.
  • Manually refine the segmentation to correct for errors, ensuring the Superior Sagittal Sinus (SSS), Transverse Sinus (TS), and other structures of interest are accurately captured.
  • Generate a 3D surface model from the segmented vasculature.
• Trajectory Planning: Within the 3D environment, identify the optimal trajectory for device delivery. Assess the path from the venous access point (e.g., femoral vein) to the target implantation site (e.g., TS or distal SSS), noting points of potential vascular challenge [54].
• Validation (Optional but Recommended): For complex anatomy or in clinical translation, validate the 3D model and plan using DSA, which remains the gold standard for vascular imaging [55].

Protocol for Preclinical Safety and Feasibility Assessment

This protocol outlines the key steps for a feasibility study in a large animal model (e.g., sheep), as referenced in the search results [54].

I. Materials and Equipment

• Animal model (e.g., 70-75 kg female sheep) [54].
• Synchron Stentrode system or equivalent stent-electrode array [54].
• Apollo I 32-channel signal acquisition system or in-house recording/stimulation unit [54].
• Fluoroscopy and neuroendoscopy equipment for image-guided implantation [16].
• Physiological monitoring equipment (e.g., for ECG, blood pressure, oxygenation).

II. Procedure

• Preoperative Planning: Conduct preoperative MRI and 3D vascular reconstruction as described in Protocol 3.1 [54].
• Animal Preparation: Anesthetize the animal and maintain under general anesthesia. Continuously monitor vital signs throughout the procedure [54].
• Stentrode Implantation:
  • Gain percutaneous access to the venous system (e.g., femoral vein).
  • Under fluoroscopic guidance, navigate the stent-electrode delivery catheter through the venous system to the target site (TS or SSS).
  • Deploy the stent-electrode array precisely at the predetermined location.
  • Use neuroendoscopy, if available, to visually confirm deployment and position [16].
• Signal Acquisition and Validation:
  • Connect the transvascular lead to the external signal acquisition system.
  • Record baseline electrocorticography (ECoG) signals from the visual or motor cortex.
  • To validate functionality, administer a convulsant agent like Pentetrozol to induce seizure-like activity. Confirm the presence of characteristic spike patterns across all sensing channels, correlated with observed physical manifestations (e.g., body twitching) [54].
• Chronic Monitoring (if applicable): For chronic studies, secure the lead subcutaneously and allow the animal to recover. Monitor for signs of infection or neurological deficit and conduct periodic signal recordings to assess long-term stability.

Visualization of Workflows

Pre-op Planning Workflow

Implantation & Validation

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials and Reagents for Stent-Electrode Research

Item Name	Function/Application	Example/Specification
Stent-Electrode Array	Core device for endovascular neural recording; a braided stent base with embedded insulated wires and tiny electrodes [54].	Synchron Stentrode system; braided stent with DFT wires and ~32 channels [54].
Signal Acquisition System	Amplifies, filters, and digitizes analog neural signals from the electrode array for analysis [54].	Apollo I 32-channel system; custom in-house recording/stimulation units [54].
MRI Contrast Agent	Intravenous agent used to enhance the visibility of the venous vasculature during preoperative MRI scans [54].	Gadolinium-based contrast agents (e.g., Gadavist, Dotarem).
Convulsant Agent (Preclinical)	Pharmacological agent used in animal models to induce controlled neural hyperactivity, validating the recording capability of the implanted array [54].	Pentetrozol; used to induce seizure-like spikes for channel validation [54].
Micro-Electrocorticography (μECoG) Array	A complementary, high-density cortical surface array for validating signals or as an alternative modality [16].	1024-channel thin-film microelectrode array for subdural placement [16].
Image-Guided Navigation System	Provides real-time imaging for accurate device delivery and deployment, minimizing invasiveness [16].	Fluoroscopy systems; neuroendoscopy; cranial micro-slit delivery techniques [16].

Evaluating Efficacy and Positioning in the Neural Interface Landscape

Endovascular stent-electrode arrays represent a transformative approach in the field of neural interfacing, offering a minimally invasive alternative to traditional neural recording methods [2]. These devices are delivered to the cerebral venous system via catheter, avoiding the need for open craniotomy and its associated risks [3]. This application note provides a systematic benchmarking of recording signal fidelity across three modalities: endovascular, subdural, and scalp recordings, with specific focus on experimental protocols for direct comparison. The quantitative data and methodologies presented herein are intended to guide researchers in validating neural interface technologies for both basic research and clinical applications, including drug development and therapeutic device testing.

The fundamental advantage of endovascular neural recording lies in its strategic positioning within blood vessels adjacent to neural targets, effectively balancing signal quality with reduced surgical invasiveness [12]. As the field progresses toward fully implantable closed-loop systems for neurological disorders, understanding the precise performance characteristics of these interfaces relative to established standards becomes paramount [56]. The following sections provide detailed performance metrics, experimental methodologies, and technical resources to facilitate rigorous evaluation of endovascular recording technologies.

Comparative Signal Fidelity Analysis

Quantitative Performance Metrics

Direct comparisons of signal quality parameters are essential for technology selection and validation. The following tables summarize key electrophysiological recording metrics across different interface modalities, based on empirical studies in preclinical models and human applications.

Table 1: Electrophysiological Recording Characteristics by Modality

Parameter	Endovascular Recording	Subdural ECoG	Scalp EEG
Spatial Resolution	Limited by vessel anatomy; comparable to subdural at specific frequencies [56]	2-6 mm [56]	>10 mm [56]
Signal Amplitude	Comparable to subdural arrays [56]	10-500 μV [56]	Significantly attenuated by skull [56]
Bandwidth	Up to 500 Hz [56]	Up to 500 Hz [56]	Typically <100 Hz
High-Frequency Oscillation Detection	Capable of recording high-frequency physiological events [3]	Excellent for high-frequency activity	Limited utility
Invasiveness	Minimally invasive (venous catheterization) [2]	Highly invasive (craniotomy required) [56]	Non-invasive
Long-term Stability	Stable recordings >12 months demonstrated; endothelialization reduces signal variability [6] [12]	Subject to glial scarring and signal degradation over time [57]	Not applicable
Clinical Risk Profile	Lower procedural risk than craniotomy; anticoagulation considerations [3]	Risk of infection, hematoma, blood-brain barrier disruption [3]	No procedural risk

Table 2: Signal Quality Metrics from Preclinical Comparative Studies

Metric	Endovascular Array	Subdural Array	Epidural Array	Notes
Signal-to-Noise Ratio (SNR)	Not significantly different from conventional sensors [56]	Reference standard	Not significantly different from endovascular [56]	Direct correlation between SNR and classification accuracy [56]
Bandwidth Characteristics	Not significantly different from conventional sensors [56]	Reference standard	Not significantly different from endovascular [56]	Bandwidth provides estimate of information quantity [56]
Decoding Accuracy	Comparable between electrode arrays [56]	Reference standard	Comparable between electrode arrays [56]	Critical for brain-machine interface applications [56]
Acute vs. Chronic Signal Stability	Highly variable before endothelialization (~14 days); stable thereafter [56]	Typically stable immediately post-implantation	Typically stable immediately post-implantation	Endothelial incorporation crucial for stable recordings [56]

Technical Considerations for Experimental Design

When benchmarking neural interfaces, researchers should account for several technical factors that significantly impact recording fidelity:

• Temporal Dynamics: Endovascular electrodes require an incorporation period (approximately 14 days) during which signals may be highly variable until the device endothelializes within the blood vessel wall [56]. Studies comparing modalities must account for this temporal dimension in experimental timelines.

• Anatomical Constraints: The placement of endovascular arrays is constrained by vascular anatomy, which may limit optimal positioning relative to target neural structures [12]. Computational modeling of vessel trajectories is recommended during experimental planning.

• Signal Contamination: Endovascular recordings may contain artifacts from cardiac pulsatility and respiration that require specific signal processing approaches for mitigation [12]. Adaptive filtering techniques referencing simultaneous ECG recordings have proven effective.

Experimental Protocols for Comparative Studies

Protocol 1: Simultaneous Multi-Modal Recording Setup

Objective: To directly compare signal fidelity characteristics across endovascular, subdural, and scalp recording modalities in a controlled experimental setting.

Materials:

• Endovascular stent-electrode array (e.g., Stentrode)
• Subdural electrode array (e.g., ECoG grid)
• Scalp EEG electrode array
• Multi-channel neural signal acquisition system
• Synchronization module for multiple devices
• Signal processing software (MATLAB, Python with MNE, or similar)

Procedure:

• Animal Preparation: Anesthetize subject (ovine model recommended based on established literature) and position in stereotactic frame [56].
• Surgical Exposure: Perform craniotomy to expose dura mater for subdural array placement.
• Venous Access: Establish femoral venous access using Seldinger technique under fluoroscopic guidance.
• Endovascular Deployment: Navigate stent-electrode array to target venous structure (superior sagittal sinus recommended for motor cortex applications) using endovascular techniques [2] [3].
• Array Placement: Position subdural array on cortical surface adjacent to endovascular target zone.
• Scalp Electrode Placement: Apply scalp EEG electrodes following international 10-20 system positioning.
• System Connection: Connect all electrode arrays to synchronized recording systems with common reference.
• Signal Validation: Record spontaneous activity followed by evoked potentials (median nerve stimulation recommended) to validate all systems are capturing neural events [56].
• Data Collection: Conduct continuous recording session of sufficient duration (minimum 2 hours recommended) to capture varied brain states.

Analysis Workflow:

• Preprocess signals with appropriate bandpass filtering (0.5-500 Hz for local field potentials)
• Extract epochs during evoked responses and resting states
• Calculate signal-to-noise ratio, bandwidth, and spatial resolution metrics
• Perform statistical comparisons across modalities using repeated measures ANOVA

Protocol 2: Chronic Recording Stability Assessment

Objective: To evaluate long-term signal stability and biocompatibility of endovascular arrays compared to subdural implants.

Materials:

• Chronic implantable endovascular array
• Subdural control array
• Wireless recording system or percutaneous connector
• Histological processing equipment
• Immunohistochemistry reagents for glial markers (GFAP, Iba1)

Procedure:

• Initial Implantation: Follow Protocol 1 for initial array placements.
• Baseline Recording: Collect comprehensive neural dataset immediately post-implantation.
• Longitudinal Monitoring: Conduct weekly recording sessions for minimum 12-week period.
• Signal Metrics Tracking: Quantify signal amplitude, noise floor, and viable electrode count at each timepoint.
• Endpoint Analysis: Perfuse-fixate subject and extract brain tissue for histological processing.
• Tissue Response Assessment: Section and stain tissue for glial fibrillary acidic protein (GFAP) and ionized calcium-binding adapter molecule 1 (Iba1) to quantify glial scarring [57].
• Electrode-Tissue Integration: Evaluate endothelialization of endovascular arrays using scanning electron microscopy.

Analysis Workflow:

• Calculate signal stability index (SSI) as correlation coefficient of evoked response waveforms across sessions
• Quantify glial scar thickness around subdural implants
• Assess vascular patency and endothelial coverage for endovascular arrays
• Perform linear mixed-effects modeling of signal quality over time

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials for Endovascular Neural Interface Research

Category	Specific Reagents/Resources	Research Function	Example Applications
Electrode Materials	Platinum/Platinum Black [6]	Enhanced charge injection capacity for stimulation	Endovascular motor cortex stimulation [6]
	Zirconium oxide insulation [6]	Biocompatible electrode passivation	Chronic implant encapsulation
	Nitinol stent framework [6]	Self-expanding structural support	Stentrode deployment platform
Animal Models	Ovine model [2] [56]	Cerebral venous system comparable to humans	Preclinical safety and efficacy testing
	Parkinsonian sheep model [58]	Neurological disease modeling	Therapeutic stimulation validation
Signal Processing	Custom decoding algorithms [56]	Movement intent classification	Brain-machine interface control
	Adaptive filtering techniques	Artifact reduction from cardiac pulsatility	Signal quality enhancement
Implantation Equipment	Medical-grade catheters [58]	Minimally invasive device delivery	Stentrode deployment to target vessels
	Fluoroscopic guidance systems [2]	Real-time device navigation	Precise vascular positioning

Technical Implementation Considerations

Electrode Design and Optimization

Recent advances in electrode materials have demonstrated that platinum black coatings substantially improve the performance characteristics of endovascular interfaces. These modifications increase electroactive surface area, resulting in enhanced charge injection capacity (21.9 μC cm⁻² for uncoated platinum vs. 64.9 μC cm⁻² for platinum black coated electrodes) critical for both recording and stimulation applications [6]. This enhancement enables safer neural stimulation with greater electrode-neuron distances while maintaining efficacy.

Material selection for flexible electrode arrays continues to evolve, with emerging technologies utilizing ultra-thin substrates such as hexagonal boron nitride and graphene to create conformal interfaces with neural tissues [59]. These advances address the fundamental challenge of mechanical mismatch between implanted devices and biological tissues, which remains a significant factor in chronic inflammatory responses and long-term signal stability [60].

Signal Processing and Decoding Methodologies

The extraction of meaningful neural commands from endovascular recordings requires specialized signal processing approaches tailored to the unique characteristics of the vascular environment. Studies have established a direct correlation between signal-to-noise ratio and classification accuracy in endovascular arrays, with decoding performance comparable to traditional subdural and epidural interfaces [56].

Implementing these processing pipelines requires consideration of the distinctive signal propagation environment presented by the vascular system. The combination of highly conductive blood vessel walls and cerebrospinal fluid creates specific impedance characteristics that influence signal recording, particularly in lower frequency ranges [56]. Computational modeling of these biophysical properties is recommended when developing novel endovascular interfaces.

This application note provides comprehensive benchmarking methodologies and technical protocols for evaluating endovascular stent-electrode arrays against established neural recording modalities. The comparative data demonstrates that endovascular approaches achieve signal fidelity comparable to subdural arrays while offering significantly reduced invasiveness. These capabilities position endovascular interfaces as a promising platform for chronic neural recording and stimulation applications in both basic research and clinical therapeutics.

The experimental frameworks outlined enable standardized assessment of neural interface technologies across multiple performance dimensions, facilitating direct comparison of emerging technologies against existing standards. As the field advances, these protocols may be extended to evaluate additional parameters including long-term biocompatibility, stimulation efficacy, and functional outcomes in disease-specific applications.

---

Endovascular stent-electrode arrays represent a paradigm shift in brain-computer interface (BCI) technology, enabling neural recording via placement within cerebral blood vessels. This minimally invasive approach circumvents the need for open craniotomy, which is a hallmark of traditional invasive BCIs such as intracortical microelectrode arrays and electrocorticography (ECoG) grids. The safety profile of any neural interface is paramount for its clinical translation. This document provides a comparative analysis of complication rates between endovascular and traditional invasive BCIs, structured with quantitative data tables, detailed experimental protocols, and visual workflows to aid researchers and drug development professionals in evaluating these technologies.

---

Comparative Safety Data Tables

The following tables summarize key safety data from preclinical and clinical studies, highlighting the relative risks associated with each BCI modality.

Table 1: Primary Safety Outcomes in Human Clinical Studies

Safety Outcome	Endovascular BCI (Stentrode, n=4) [4]	Traditional Invasive BCI (Aggregate Data) [61]
Serious Adverse Events (Device-Related)	0% (0/4 patients over 12 months)	Not fully quantified; inherent risks from craniotomy include hemorrhage and infection [61]
Vessel Occlusion	0% (0/4 patients)	Not Applicable
Device Migration	0% (0/4 patients)	Not systematically reported
Signal Stability	Stable bandwidth (mean 233 Hz) over 12 months	Signal degradation possible due to tissue scarring [61]

Table 2: Preclinical Safety Observations from Ovine Models

Parameter	Endovascular BCI (Stentrode) [62]	Traditional Invasive BCI (Utah Array) [23] [61]
Cortical Vein Occlusion Rate	37% (3/8 veins in 3 animals); no clinical sequelae observed	Not Applicable
Subdural Hematoma from Implantation	Occurred with catheters >4F; 0% with 2F/4F catheters	A known risk of dura penetration during craniotomy [61]
Chronic Tissue Response	Minimal intimal encapsulation in vessel [62]	Glial scarring and chronic inflammation around electrodes [23] [61]

---

Experimental Protocols for Safety Assessment

To ensure reproducible safety evaluations, the following standardized protocols are provided.

Protocol for Endovascular BCI Implantation and Safety Monitoring

This protocol is adapted from the first-in-human SWITCH study (NCT03834857) and preclinical ovine models [4] [62].

• Objective: To safely implant an endovascular BCI (Stentrode) and monitor for procedure- and device-related adverse events.
• Pre-implant Phase:
  • Subject Selection: Enroll patients with severe bilateral upper-limb paralysis (e.g., from ALS). Confirm preserved motor cortex activation via fMRI and suitable venous anatomy via CT venography.
  • Pre-medication: Initiate dual antiplatelet therapy (e.g., aspirin and clopidogrel) two weeks pre-implant to mitigate thrombosis risk.
• Implantation Phase:
  • Procedure: Under general anesthesia, perform percutaneous access of the internal jugular vein.
  • Navigation: Navigate a ≤4F guide catheter under digital subtraction angiography (DSA) guidance to the target location in the superior sagittal sinus, adjacent to the precentral gyrus.
  • Deployment: Deploy the stent-electrode array. Tunnel the transvascular lead to a subcutaneous receiver unit in the infraclavicular region.
• Post-implant Safety Monitoring:
  • Primary Endpoint: Monitor for device-related serious adverse events (SAEs) for 12 months.
  • Secondary Endpoints:
    • Assess vessel patency and device position via CT venography at 3 and 12 months.
    • Record all adverse events, graded by severity and relation to the device/procedure.
  • Feasibility Endpoints: Evaluate signal fidelity (bandwidth) and stability through regular training sessions where patients control a computer.

Protocol for Traditional Invasive BCI (Intracortical) Safety Assessment

This protocol synthesizes methodologies from long-term intracortical BCI studies, primarily using devices like the Utah Array [61].

• Objective: To assess the safety and long-term stability of intracortical microelectrode arrays.
• Implantation Phase:
  • Procedure: Perform a craniotomy under general anesthesia to expose the cortical surface.
  • Placement: Insert the microelectrode array (e.g., Utah Array) into the precentral gyrus using a pneumatic inserter.
• Post-implant Safety & Stability Monitoring:
  • Primary Endpoint: Monitor for SAEs related to the craniotomy or device, including intracranial hemorrhage, infection, and seizure.
  • Histological Endpoint (Preclinical): In animal models, perform histopathological analysis post-explanation to quantify glial scarring (gliosis) and neuronal loss around the electrode tracks.
  • Signal Stability Assessment: Track signal-to-noise ratio (SNR) and single-unit yield over months to years to correlate with tissue response.

---

Visualization of BCI Workflows and Safety Considerations

The following diagrams illustrate the core workflows and safety-related pathways for both BCI types.

Endovascular BCI Implantation and Signal Pathway

This diagram outlines the key steps for implanting an endovascular BCI and the subsequent neural signal pathway.

Diagram 1: Endovascular BCI Workflow The workflow for implanting an endovascular BCI (Stentrode) and processing neural signals, highlighting critical safety checkpoints related to the minimally invasive procedure [4] [62]. SSS: Superior Sagittal Sinus; IRTU: Implantable Receiver-Transmitter Unit.

Tissue Response to Invasive BCIs

This diagram contrasts the chronic tissue response pathways for endovascular and traditional intracortical implants.

Diagram 2: Tissue Response Pathways A comparison of the biological pathways activated by different BCI implantation methods, leading to divergent long-term signal stability outcomes [23] [61] [62].

---

The Scientist's Toolkit: Research Reagent Solutions

The table below lists essential materials and their functions for research in endovascular and traditional invasive BCI development.

Table 3: Essential Research Materials for BCI Development

Material / Reagent	Function in Research	Relevance to BCI Type
Stentrode Device (Synchron)	Endovascular electrode array for recording cortical signals from within a blood vessel.	Endovascular BCI [2] [4]
Utah Array (Blackrock Neurotech)	Intracortical microelectrode array for high-fidelity single-neuron recording.	Traditional Invasive BCI [23] [61]
Dual Antiplatelet Therapy (e.g., Aspirin, Clopidogrel)	Prevents stent and lead-associated thrombosis.	Endovascular BCI [4] [62]
Flexible Polymer Substrates (e.g., Polyimide)	Base material for creating soft, conformable electrode arrays to minimize mechanical mismatch with tissue.	Both (Advanced designs) [23]
Graphene-Based Electrodes (e.g., InBrain Neuroelectronics)	High-resolution, biocompatible material for neural recording and stimulation.	Both (Emerging technology) [63]
Fleuron Material (Axoft)	An ultrasoft implantable material designed to reduce glial scarring and improve long-term signal stability.	Traditional Invasive BCI (Novel approach) [63]

---

The current body of evidence indicates that endovascular BCIs present a distinct and potentially safer clinical profile compared to traditional invasive BCIs. The primary advantage is the elimination of open brain surgery, thereby avoiding associated risks like direct parenchymal hemorrhage and infection. While endovascular implantation carries its own unique risks, such as vessel injury and thrombosis, early clinical data demonstrate that these can be mitigated with careful patient selection, procedural technique, and pharmacological management. The long-term biocompatibility and functional stability of both interfaces remain active areas of research, with material science innovations poised to benefit both platforms. This comparative safety analysis provides a foundational framework for researchers developing and evaluating next-generation minimally invasive neural recording technologies.

Endovascular stent-electrode arrays, such as the Stentrode, represent a paradigm shift in brain-computer interface (BCI) technology by enabling neural recording via the cerebral venous system, thus avoiding the need for open craniotomy [2]. For widespread clinical adoption, particularly in the treatment of severe paralysis, demonstrating long-term signal stability is paramount. This document synthesizes current evidence and methodologies for achieving stable chronic recordings, framing the discussion within the broader context of minimally invasive neural recording research. The focus is on providing application notes and detailed protocols to guide researchers and drug development professionals in evaluating and validating the chronic performance of these devices.

Quantitative Evidence of Chronic Performance

Long-term performance data for endovascular BCIs is emerging from both preclinical and early clinical studies. The following tables summarize key quantitative findings that evidence stable recordings.

Table 1: Preclinical Evidence of Chronic Recording Performance (Ovine Model)

Performance Metric	Reported Data / Outcome	Significance / Implication
Recording Stability	Stable neural recordings demonstrated over implantation period [2].	Provides initial proof-of-concept that endovascular electrodes can maintain functional contact with neural tissue over time.
Neural Signal Fidelity	Recording fidelity is comparable to traditional subdural electrode arrays [2].	Validates the endovascular approach as a viable alternative to more invasive surgical techniques for signal acquisition.
Key Challenges Identified	Thrombosis risk, long-term electrode stability, anatomical variability [2].	Informs mitigation strategies in device design and post-operative care, crucial for chronic safety and efficacy.

Table 2: Clinical Evidence from Studies in Amyotrophic Lateral Sclerosis (ALS) Patients

Performance Metric	Reported Data / Outcome	Significance / Implication
Patient Number & Outcome	Six ALS patients successfully used the BCI for digital communication [2].	Demonstrates initial clinical feasibility and functional utility in the target patient population.
Safety Profile	Minimal vascular complications reported across studies [2].	Supports the minimally invasive safety advantage of the endovascular approach over intracortical implants.
Long-term Stability	Stable long-term signals reported in human trials [2].	Early indicator of the potential for chronic implantation, though long-term clinical data remains scarce.

Underlying Biological Mechanisms and Signaling Pathways

The long-term stability of any neural implant is governed by the biological response it elicits. Conventional rigid implants trigger a chronic Foreign Body Response (FBR), leading to glial scar formation and neuronal death, which isolates the electrode and degrades signal quality [64]. Endovascular devices, by residing within a blood vessel, may avoid direct parenchymal trauma. However, they still interface with the vessel wall, necessitating high biocompatibility to minimize thromboinflammation—a combined response involving thrombosis (blood clotting) and intimal hyperplasia (vessel wall thickening) [2]. The following diagram illustrates the key signaling pathways and cellular responses involved in the stability of endovascular implants.

Experimental Protocol for Chronic Validation

This protocol outlines a methodology for validating the long-term performance and biological integration of an endovascular stent-electrode array, based on reviewed literature.

4.1. Objective To assess the chronic recording stability, safety, and biocompatibility of an endovascular BCI in a large animal model (e.g., ovine) over a defined implantation period (e.g., 12 months).

4.2. Materials and Reagents Table 3: Research Reagent Solutions and Essential Materials

Item / Reagent	Function / Application
Stentrode Device	The endovascular stent-electrode array itself; the primary subject of testing for recording and biostability [2].
Antiplatelet/Anticoagulant Regime	(e.g., Clopidogrel, Aspirin). Critical for preventing thrombosis on the device post-implantation, a key safety parameter [2].
Angiography Suite	For precise, image-guided endovascular implantation of the device into the target cerebral vein [2].
Neural Signal Acquisition System	Hardware and software for amplifying, filtering, and recording electrophysiological signals (e.g., local field potentials) from the electrode array.
Histological Stains (e.g., H&E, GFAP)	For post-mortem analysis of tissue integration, inflammation, and assessment of glial scarring in the surrounding brain tissue [64].

4.3. Procedure

• Pre-Implantation:
  • Obtain ethical approval and conduct pre-operative baseline imaging (e.g., angiography) to map venous anatomy.
  • Initiate antiplatelet therapy (e.g., dual therapy with Aspirin and Clopidogrel) prior to implantation.

• Implantation Surgery:

  • Perform the procedure in an angiography suite under general anesthesia and sterile conditions.
  • Using endovascular techniques, navigate the delivery catheter containing the stent-electrode array to the target cerebral vein (e.g., superior sagittal sinus).
  • Deploy the array under fluoroscopic guidance, ensuring apposition against the vessel wall.
  • Close access sites and recover the animal according to established surgical protocols.

• Chronic Recording & Monitoring:

  • Data Collection: Conduct regular neural recording sessions (e.g., weekly) in both resting and task-engaged states. Record Local Field Potentials (LFPs) and, if possible, multi-unit activity.
  • Signal Analysis: Quantify signal quality metrics, including Signal-to-Noise Ratio (SNR), root mean square (RMS) of the background noise, and number of recordable channels over time.
  • Health Monitoring: Clinically monitor the animal for neurological deficits and continue antiplatelet therapy. Conduct periodic imaging (e.g., MRI, CT) to assess device position and vessel patency.

• Terminal Analysis:

  • At the endpoint, perform a final recording session.
  • Euthanize the animal and perform a necropsy.
  • Histology: Perfuse-fix the brain and carefully remove the device and surrounding tissue. Process tissue for histological staining (H&E for general morphology, GFAP for reactive astrocytes, and markers for macrophages/microglia). Analyze for evidence of thrombosis, intimal hyperplasia, and parenchymal inflammation [64] [2].

The following workflow diagram summarizes this experimental protocol.

The collective evidence from preclinical and early clinical studies indicates that endovascular stent-electrode arrays can achieve stable neural recordings over chronic timescales, with a promising safety profile. The pathway to stability is critically dependent on managing the thromboinflammatory response through device biocompatibility and pharmacological intervention. The provided protocols and analyses offer a framework for researchers to rigorously evaluate and contribute to the development of these transformative minimally invasive neural interfaces. Future efforts must focus on optimizing long-term biocompatibility, signal processing, and generating robust long-term clinical data to fully realize the potential of endovascular BCIs.

The field of minimally invasive brain-computer interfaces (BCIs) is rapidly advancing beyond endovascular stent-electrode arrays. While stent-electrode technology represents a significant breakthrough by utilizing blood vessels for cortical access, two emerging approaches—endocisternal and intraventricular interfaces—offer complementary pathways to neural structures that are difficult to reach via the vascular system. These approaches leverage the cerebrospinal fluid (CSF)-filled spaces surrounding the brain and spinal cord, providing unprecedented access to deep brain structures, the entire brain convexity, and the spinal cord with minimal tissue disruption.

Endocisternal neural interfaces approach brain and spinal cord targets through the inner and outer CSF-filled spaces, including the cranial subarachnoid space and ventricles [65]. In parallel, intraventricular interfaces (IVIs) represent a technological leap for interfacing with subcortical nuclei surfaces within the intraventricular cerebrospinal fluid [66]. This application note details the methodologies, experimental protocols, and technical specifications of these emerging platforms, providing researchers with practical guidance for implementing these technologies in neuroscience research and therapeutic development.

Endocisternal Neural Interfaces

The endocisternal approach represents a paradigm shift in neural interface design by utilizing the natural cerebrospinal fluid compartments as navigation pathways and implantation sites. This technology combines flexible electrode arrays with wireless miniature magnetoelectrically powered bioelectronics that can be freely navigated percutaneously from the spinal space to the cranial subarachnoid space, and from the cranial subarachnoid space to the ventricles [65]. This unique capability provides access to the entire brain convexity, deep brain structures within the ventricles, and the spinal cord from the spinal subarachnoid space—addressing a critical limitation of endovascular approaches that are constrained by vascular anatomy.

Key advantages of this platform include its explantation capability after chronic implantation and repositioning flexibility, features not typically available with endovascular probes after endothelialization occurs [65]. The technology has demonstrated both recording and stimulation functions in sheep models, showing particular promise for chronic and transient therapies, especially in stroke rehabilitation and epilepsy monitoring applications.

Silk-Enabled Intraventricular Interfaces (IVI)

The silk-enabled conformal intraventricular interface represents a sophisticated approach to monitoring periventricular neural structures. This technology features a deformable microelectrode array (dMEA) paired with a silk scaffold that enables minimally invasive implantation into the lateral ventricles with the assistance of commonly used clinical catheters [66]. Once deployed in the cerebrospinal fluid environment, the IVI self-unfolds to conformally attach to the surfaces of periventricular neural structures, capturing high-quality signals by virtue of the microelectrode's in-plane shielding design.

The IVI's innovative use of silk fibroin provides shape memory properties that enable temporary miniaturization for catheter-based delivery followed by CSF-triggered self-unfolding at the target site [66]. This platform has been validated in parkinsonian ewes, where it successfully detected deep brain abnormalities and achieved stable, biocompatible in vivo recordings for four weeks, demonstrating its potential for chronic monitoring and circuit analysis of diseased deep brain regions.

Comparative Performance Metrics

Table 1: Comparative Analysis of Minimally Invasive Neural Interface Platforms

Parameter	Endocisternal Interface	Intraventricular Interface (IVI)	Endovascular Stentrode
Access Route	Spinal/cranial subarachnoid space, ventricles [65]	Lateral ventricles via catheter [66]	Cortical veins/venous sinuses [67]
Key Structures Accessible	Entire brain convexity, deep brain ventricles, spinal cord [65]	Periventricular nuclei (caudate nucleus, thalamus) [66]	Cortical surfaces adjacent to major veins [12]
Chronic Implantation Duration	Demonstrated explantation after chronic implantation [65]	4 weeks (demonstrated in parkinsonian sheep) [66]	Up to 190 days (sheep), 1+ years (humans) [11] [67]
Unique Capabilities	Repositionable, explantable, wireless navigation [65]	Self-unfolding silk scaffold, conformal attachment [66]	Endothelialization, permanent implantation [11]
Primary Applications	Stroke rehabilitation, epilepsy monitoring [65]	Parkinson's disease monitoring, deep brain circuit analysis [66]	Paralysis (BCI for communication/control) [67]
Signal Quality	Recording and stimulation functions demonstrated [65]	High-quality signals with in-plane shielding [66]	Comparable to epidural arrays [12]

Experimental Protocols and Methodologies

Implantation Workflow for Intraventricular Interfaces

Table 2: Surgical Implantation Protocol for Silk-Enabled IVI

Procedure Step	Technical Specifications	Purpose and Rationale
Device Preparation	dMEA (14μm thick, dual-metal layer, polyimide-encapsulated) integrated with shape-memory silk scaffold [66]	Ensure proper self-unfolding capability and electrode functionality
Catheter Assembly	Integration with medical catheters (compatible with 2.2mm inner diameter) [66]	Enable minimally invasive implantation using standard neurosurgical tools
Surgical Navigation	Stereotactic guidance to lateral ventricles [66]	Precise positioning over target periventricular structures
Device Deployment	Catheter-based delivery with CSF-triggered self-unfolding [66]	Achieve conformal contact with neural tissue without direct manipulation
Secure Fixation	Skull-mounted base (high-strength 3D-printed nylon) [66]	Protect backend components and ensure recording stability
Biocompatibility Management	Dexamethasone integration via silk fibroin drug delivery [66]	Alleviate acute neuroinflammatory reactions

Endocisternal Interface Navigation and Placement

The endocisternal interface deployment follows a distinct protocol leveraging the cerebrospinal fluid pathways:

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Materials and Reagents for Endocisternal and Intraventricular Research

Item	Specifications	Research Application
Deformable Microelectrode Array (dMEA)	14μm thickness, dual-metal layer, polyimide encapsulation, in-plane shielding [66]	High-quality neural signal acquisition from curved surfaces
Silk Fibroin Scaffold	Shape-memory properties, CSF-triggered self-unfolding, drug-eluting capability [66]	Miniaturized device delivery and conformal neural attachment
Magnetoelectrically Powered Bioelectronics	Wireless, miniature design for percutaneous navigation [65]	Endocisternal interface power and data transmission
Medical Implantation Catheters	Compatible with standard neurosurgical tools (2.2mm inner diameter) [66]	Minimally invasive device delivery to target compartments
3D-Printed Nylon Base	High-strength, skull-mounted protective housing [66]	Chronic implantation stability and backend component protection
Dexamethasone-Loaded Silk	Anti-inflammatory drug integration in silk fibroin matrix [66]	Acute neuroinflammatory response management post-implantation

Quantitative Data Analysis and Performance Metrics

Signal Quality and Stability Assessments

Both endocisternal and intraventricular interfaces have demonstrated robust electrophysiological recording capabilities in large animal models. The IVI platform has shown particular efficacy in detecting deep brain abnormalities in parkinsonian sheep models, with the capability to monitor the electrophysiological effects of levodopa treatment [66]. The conformal attachment enabled by the silk scaffold ensures stable contact with periventricular structures, facilitating high-accuracy discrimination of neural activity across multiple microelectrode sites.

The endocisternal approach provides broad coverage capabilities, with demonstrated access to the entire brain convexity, deep brain structures within the ventricles, and the spinal cord from the spinal subarachnoid space [65]. This extensive reach, combined with the platform's explantation and repositioning capabilities, offers unique advantages for longitudinal studies requiring adaptive experimental designs.

Biocompatibility and Chronic Performance

Long-term biocompatibility represents a critical consideration for chronic neural interfaces. The silk-enabled IVI has demonstrated stable recording performance for four weeks in parkinsonian sheep models, with immunohistochemical analysis confirming good biocompatibility of all components in contact with neural tissue—including the dMEA, silk scaffold, tantalum marker, and soldering pads of the flexible printed circuit board [66].

The endocisternal interface similarly maintains functionality during chronic implantation while offering the unique advantage of explantation capability—a feature not typically available with endovascular probes after endothelialization occurs [65]. This characteristic may be particularly valuable for temporary monitoring applications or for patients who may require device removal due to changing clinical needs.

Endocisternal and intraventricular interfaces represent significant advancements in the minimally invasive neural interface landscape, complementing and extending the capabilities of endovascular stent-electrode arrays. By leveraging the cerebrospinal fluid compartments as natural access pathways, these technologies overcome fundamental limitations of vascular-constrained approaches, particularly for deep brain and spinal targets.

The silk-enabled intraventricular interface offers sophisticated access to periventricular neural structures with self-unfolding conformal attachment capabilities, while the endocisternal platform provides unparalleled navigation flexibility throughout the entire neuraxis. Together, these approaches expand the toolbox available to neuroscientists and clinical researchers investigating deep brain circuits, developing novel neuromodulation therapies, and advancing our understanding of neurological disease progression.

As these technologies continue to mature through large-animal validation and early-stage clinical trials, they hold particular promise for conditions such as Parkinson's disease, epilepsy, stroke rehabilitation, and spinal cord injury—conditions where traditional surgical approaches carry significant risks and where current minimally invasive options lack adequate target access.

Gaps in Evidence and the Need for Large-Scale Clinical Trials

Endovascular stent-electrode arrays represent a paradigm shift in brain-computer interface (BCI) technology, offering a minimally invasive alternative to traditional intracranial implants. By leveraging the vascular system as a pathway to the brain, these devices avoid the need for open craniotomy, thereby reducing surgical risks and potentially enabling wider clinical adoption [68] [2]. The most advanced such device, the Stentrode, has demonstrated feasibility in early human trials, allowing paralyzed patients to control digital devices for communication and daily activities [4] [23]. However, as the field progresses toward broader clinical application, significant evidence gaps remain unresolved. This application note systematically outlines these gaps, summarizes existing clinical data, and provides detailed protocols for future large-scale trials necessary to establish endovascular BCIs as mainstream clinical tools.

Current State of Clinical Evidence

Early feasibility studies have provided promising initial data on the safety and performance of endovascular stent-electrode arrays. The table below summarizes key outcomes from available human clinical studies.

Table 1: Summary of Clinical Evidence from Endovascular BCI Trials

Study/Device	Participant Profile	Primary Safety Outcomes	Efficacy & Signal Performance	Duration	Evidence Level
SWITCH Study (Stentrode) [4]	4 patients with severe bilateral upper-limb paralysis (ALS/PLS)	No device-related serious adverse events; no vessel occlusion or device migration.	Successful computer control for texting, emailing, online shopping; stable signal bandwidth (233 ±16 Hz).	12-month follow-up	First-in-human case series
COMMAND EFS (Stentrode) [46]	5 patients with paralysis	Favorable safety profile; minimal vascular complications.	Stable motor-related neural modulation in high-frequency bands (30-200 Hz) over 12 months; impedances stable.	Up to 12 months	Early Feasibility Study
Synchron Stentrode [23]	Multiple patients with paralysis	No serious adverse events reported over 12 months.	Enabled digital communication and control via thought.	12 months	Early Feasibility

Table 2: Quantitative Signal Fidelity Metrics from Preclinical and Clinical Studies

Signal Parameter	Preclinical Findings	Clinical Findings (Stentrode)	Comparison with Traditional ECoG
Signal Bandwidth	High-quality recordings demonstrated in ovine models [2]	Mean 233 Hz (±16 Hz), stable over 12 months [4]	Reported as comparable to subdural arrays [2]
Signal Stability	Stable long-term recordings in ovine models [2]	Resting state band power and impedance stable over 12 months [46]	Potential advantage due to reduced tissue scarring [6]
Frequency Bands	Not specified	Motor modulation in high gamma (30-200 Hz) [46]	Similar usable frequency ranges for control
Single-Unit Resolution	Achieved in sheep using uFINE-I device [10]	Not achieved in current Stentrode trials; records population signals [4]	Lower than intracortical microelectrodes

Critical Evidence Gaps

Despite encouraging early results, the evidence base for endovascular BCIs lacks the breadth and depth required for regulatory approval and widespread clinical deployment. The following critical gaps must be addressed through structured, large-scale investigation.

Limited Clinical Population Diversity and Long-Term Data

Current studies involve small, selective cohorts (primarily individuals with ALS and severe paralysis) with follow-up limited to 12 months [4] [46]. The long-term viability (>5 years) of the implants remains unproven. Key unanswered questions include:

• Disease Progression Impact: How does progressive neurodegeneration, as in ALS, affect signal stability and decoder performance over extended periods?
• Long-Term Biocompatibility: What are the chronic effects of the implant on the venous wall, and what is the long-term risk of thrombosis or neointimal hyperplasia?
• Broader Applications: Can this technology be effectively applied to other conditions, such as spinal cord injury, stroke, or muscular dystrophy?

Technological and Material Optimization

The optimal configuration of endovascular electrodes remains an active area of research. Current gaps include:

• Electrode Materials: While platinum-iridium is standard, novel coatings like platinum black significantly improve charge injection capacity for stimulation, a feature not yet validated in long-term human trials [6].
• Signal Resolution: Current clinical devices record population-level signals (vECoG). Next-generation devices like the uFINE-I have demonstrated single-unit recording in sheep [10], but this capability has not been translated to humans.
• Stimulation Capability: The ability to not only record from but also stimulate neural tissue via an endovascular approach is in its infancy. Safe and effective stimulation parameters require extensive validation [6].

Comparative Effectiveness and Standardized Metrics

A significant gap is the lack of head-to-head comparisons with established technologies.

• Vs. Intracortical Arrays: How does the performance of endovascular BCIs for digital control compare to that of intracortical arrays (e.g., from Neuralink or Paradromics) in terms of speed, accuracy, and bandwidth of communication [69] [23]?
• Vs. Surface ECoG: A direct comparison of signal fidelity, stability, and clinical utility between endovascular and subdural/epidural ECoG arrays is lacking [68].
• Standardized Outcomes: The field lacks consensus on standardized metrics for reporting BCI performance, making cross-study comparisons difficult.

Proposed Framework for Large-Scale Clinical Trials

To address these gaps, a structured, multi-phase clinical trial program is essential. The following protocols outline the key components.

Pivotal Trial Design Protocol

Objective: To confirm safety and demonstrate efficacy of an endovascular BCI for restoring digital communication in a larger, more diverse population.

• Study Design: Prospective, multicenter, randomized controlled trial with an adaptive design.
• Participants: 100-150 patients with severe motor impairment (ALS, spinal cord injury, brainstem stroke). Key inclusion criteria: preserved motor cortex activity on fMRI, suitable venous anatomy on CT venography, and life expectancy >2 years [4].
• Intervention: Implantation of endovascular stent-electrode array (e.g., Stentrode) in the superior sagittal sinus.
• Control Group: Best standard of care (e.g., eye-tracking systems) or an active control with a non-invasive BCI.
• Primary Endpoints:
  • Safety: Incidence of device-related serious adverse events (e.g., venous thrombosis, device migration, hemorrhage) at 24 months.
  • Efficacy: Proportion of patients achieving a pre-specified performance threshold in a standardized communication task (e.g., >5 correct characters per minute without word prediction) [4].
• Secondary Endpoints:
  • Signal fidelity and stability metrics (bandwidth, SNR, impedance) over 24 months.
  • Quality of life measures (e.g., IND-QLF).
  • Usability and user satisfaction scores.

Advanced Signal Characterization Protocol

Objective: To systematically evaluate the properties and stability of vascular ECoG (vECoG) signals.

• Methodology:
  • Recording Setup: Neural data is acquired from the implanted stent-electrode array, connected to a subcutaneous unit that transmits wirelessly to an external controller [4] [46].
  • Task Paradigm: Participants perform standardized attempted movements (e.g., ankle, wrist, or tongue movements) cued by a visual stimulus, interspersed with rest periods.
  • Data Acquisition: Record broadband neural activity (e.g., 0.5-500 Hz) during multiple blocks of trials in weekly sessions for the first month, then monthly.
  • Signal Processing:
    • Spectral Analysis: Compute power spectral density (PSD) and spectrograms time-locked to the movement cue.
    • Modulation Strength: Quantify event-related synchronization (ERS) and desynchronization (ERD) in standard frequency bands (e.g., beta: 13-30 Hz, low gamma: 30-70 Hz, high gamma: 70-200 Hz) [46].
    • Stability Metrics: Calculate impedance and band power at rest across sessions to assess chronic stability.

The workflow for this characterization is outlined below.

Comparative Benchmarking Protocol

Objective: To directly compare the performance of endovascular BCIs with other invasive and non-invasive interfaces.

• Methodology:
  • Cross-Sectional Study: Recruit cohorts of users with different implanted BCIs (endovascular, intracortical, subdural ECoG) and a control group using non-invasive BCIs.
  • Standardized Tasks: All participants complete a common set of tasks in a controlled environment:
    • Closed-Loop Control: A cursor-to-target task.
    • Communication: A typing task, measuring characters per minute and accuracy.
    • Robotic Control: If applicable, a simple reach-and-grasp task.
  • Outcome Metrics:
    • Performance: Throughput (bits/min), task completion time, accuracy.
    • Usability: System setup time, daily calibration requirements.
    • Safety: Complication rates and severity.

The Scientist's Toolkit: Research Reagent Solutions

Successful research and development in this field rely on specialized materials and devices. The following table details key components.

Table 3: Essential Research Materials and Reagents for Endovascular BCI Research

Item Name	Specification / Example	Primary Function in Research
Stent-Electrode Array	Stentrode (Synchron); Nitinol stent with 16 Pt/Ir electrodes [4]	The core implantable device for minimally invasive neural signal recording.
Anti-Thrombotic Coatings	Heparin, phosphorylcholine	To reduce thrombogenicity of the implanted device within the blood vessel [4].
Antiplatelet Therapy	Clopidogrel, Aspirin	Standard prophylactic regimen to prevent thrombosis post-implantation [4].
Electrode Coating Materials	Platinum Black (PtBlack), Iridium Oxide (IrOx) [6] [10]	To increase effective surface area, lower impedance, and enhance charge injection capacity for recording and stimulation.
Ultraflexible Substrates	Polyimide-based arrays (e.g., uFINE-I) [10]	For next-generation devices aiming for single-unit recording via micro-vessel penetration; enhances biocompatibility.
Neurointerventional Delivery System	Guide catheters, microcatheters, balloon catheters, guidewires [10]	For safe and precise endovascular navigation and deployment of the electrode array.
Signal Processing Algorithms	Support Vector Machine (SVM), Deep Learning decoders [4] [23]	To translate raw neural signals (e.g., beta/gamma power) into intentional commands for device control.
Validation Phantoms & Models	3D-printed silicone vascular models (e.g., of human venous system) [10]	For pre-clinical testing of delivery techniques and device deployment in anatomically accurate models.

Endovascular stent-electrode arrays have successfully transitioned from concept to early clinical feasibility, demonstrating an encouraging safety profile and the potential to restore critical functions to people with severe paralysis. However, the path to becoming a established clinical therapy is contingent upon addressing well-defined evidence gaps. The proposed framework for large-scale, rigorous clinical trials, coupled with ongoing technological optimization, is essential to validate long-term efficacy, safety, and comparative value. Filling these gaps will not only solidify the clinical role of endovascular BCIs but also accelerate the development of safer, more effective neural interfaces for a broader patient population.

Conclusion

Endovascular stent-electrode arrays have firmly established their feasibility and transformative potential within the neural interface landscape. By providing a minimally invasive conduit to high-fidelity neural signals, this technology successfully balances the trade-off between invasiveness and signal quality, offering a promising alternative to traditional BCIs. Key takeaways from this review confirm the technology's stable long-term recording capabilities, its successful early clinical application in enabling communication for paralyzed patients, and a favorable safety profile with manageable risks such as thrombosis. However, the path to widespread clinical adoption requires overcoming significant challenges, including the optimization of long-term electrode biocompatibility, refinement of signal processing algorithms, and demonstration of efficacy in larger, more diverse patient populations through rigorous clinical trials. Future research must focus on material science innovations to improve charge injection capacity, the development of closed-loop systems for therapeutic stimulation, and the exploration of broader clinical indications beyond motor restoration, potentially revolutionizing the treatment of a wide spectrum of neurological and psychiatric disorders.

References

• 1. A Brain-Computer Interface to Restore Autonomy to People ... [https://pubmed.ncbi.nlm.nih.gov/38377064/]
• 2. Advances in endovascular brain computer interface [https://www.sciencedirect.com/science/article/pii/S0165027025001128]
• 3. minimally invasive brain–computer interface by ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11671944/]
• 4. Assessment of Safety of a Fully Implanted Endovascular Brain ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9857731/]
• 5. Synchron's Brain-Computer Interface Evaluated in ... [https://evtoday.com/news/synchrons-brain-computer-interface-evaluated-in-command-early-feasibility-study]
• 6. Endovascular neural stimulation with platinum and ... [https://www.nature.com/articles/s41598-025-93941-2]
• 7. Signal properties and stability of a chronically implanted ... [https://pubmed.ncbi.nlm.nih.gov/41040697/]
• 8. Advances in endovascular brain computer interface [https://pubmed.ncbi.nlm.nih.gov/40355001/]
• 9. Making a case for endovascular approaches for neural ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9928900/]
• 10. Intravascular delivery of an ultraflexible neural electrode ... [https://www.nature.com/articles/s41467-024-53720-5]
• 11. Minimally invasive endovascular stent-electrode array for high-fidelity, chronic recordings of cortical neural activity | Nature Biotechnology [https://www.nature.com/articles/nbt.3428]
• 12. Over the Horizon: The Present and Future of Endovascular ... [https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00432/full]
• 13. Laser Welding of Micro-Wire Stent Electrode as a Minimally ... [https://www.mdpi.com/2072-666X/16/1/21]
• 14. The Stentrode™ System by Synchron: Architectural Design ... [https://www.auctoresonline.org/article/the-stentrode-system-by-synchron-architectural-design-and-clinical-translation-of-a-minimally-invasive-braincomputer-interface]
• 15. Real-time, neural signal processing for high-density brain ... [https://bioelecmed.biomedcentral.com/articles/10.1186/s42234-025-00177-6]
• 16. Minimally invasive implantation of scalable high-density ... [https://www.nature.com/articles/s41551-025-01501-w]
• 17. Signal acquisition of brain–computer interfaces - PMC - NIH [https://pmc.ncbi.nlm.nih.gov/articles/PMC11955058/]
• 18. A Comprehensive Review of the Role of the Latest Minimally ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12182830/]
• 19. Comparison and analysis of the efficacy and safety ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6041508/]
• 20. Is Minimally Invasive Craniotomy a More Contemporary ... [https://www.mdpi.com/2813-2475/4/3/34]
• 21. Comparative study between minimally invasive ... [https://www.nature.com/articles/s41598-021-85115-7]
• 22. Historical perspectives, challenges, and future directions of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8456563/]
• 23. BCIs in 2025: Trials, Progress, and Challenges [https://andersenlab.com/blueprint/bci-challenges-and-opportunities]
• 24. What Is Minimally Invasive Brain Surgery? [https://www.bayhealth.org/community-wellness/blog/2025/may/invasive-brain-surgery]
• 25. Over the Horizon: The Present and Future of Endovascular ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7218134/]
• 26. Experimental animal models and patient-derived platforms to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12172319/]
• 27. The Translational Benefits of Sheep as Large Animal ... [https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2022.831838/full]
• 28. Critical Elements of High-Quality Preclinical Study Protocols [https://veranex.com/blog/critical-elements-of-high-quality-preclinical-study-protocols]
• 29. Less invasive brainwave recording breakthrough [https://resou.osaka-u.ac.jp/en/research/2025/20251003_1]
• 30. Brain-wide analysis reveals movement encoding structured ... [https://www.nature.com/articles/s41593-025-02114-x]
• 31. Artificial Intelligence Approaches for EEG Signal Acquisition ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12390113/]
• 32. Neural data regulation: MIND Act of 2025 introduced by US ... [https://www.linkedin.com/posts/dianasaville_for-the-first-time-neural-data-has-entered-activity-7378877541605908481-G3ts]
• 33. U.S. Senators Propose "MIND Act" to Study and ... [https://www.dwt.com/blogs/privacy--security-law-blog/2025/10/senate-mind-act-neural-data-ftc-regulation]
• 34. New brain-computer interface allows man with ALS to ' ... [https://health.ucdavis.edu/news/headlines/new-brain-computer-interface-allows-man-with-als-to-speak-again/2024/08]
• 35. First-of-its-kind technology helps man with ALS 'speak' in ... [https://health.ucdavis.edu/news/headlines/first-of-its-kind-technology-helps-man-with-als-speak-in-real-time/2025/06]
• 36. Minimally invasive endovascular stent-electrode array for high-fidelity, chronic recordings of cortical neural activity - PubMed [https://pubmed.ncbi.nlm.nih.gov/26854476/]
• 37. Why Brain Wearables Are Making Traditional EEG Labs ... [https://globalrph.com/2025/10/why-brain-wearables-are-making-traditional-eeg-labs-obsolete-in-2025/]
• 38. Improving epilepsy monitoring using long-term, in-home-bi- ... [https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1609838/full]
• 39. High-resolution neural recordings improve the accuracy of ... [https://www.nature.com/articles/s41467-023-42555-1]
• 40. Wearable devices in neurological disorders - PubMed Central [https://pmc.ncbi.nlm.nih.gov/articles/PMC12432666/]
• 41. Trans-arterial approach for neural recording and stimulation [https://www.sciencedirect.com/science/article/abs/pii/S0967586825001523]
• 42. Architectural Design and Implantation Strategies of Brain ... [https://www.auctoresonline.org/article/architectural-design-and-implantation-strategies-of-braincomputer-interfaces-a-comparative-review-of-neuralink-synchron-precision-neuroscience-and-paradromics]
• 43. A Review: Electrode and Packaging Materials for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7873964/]
• 44. Overcoming failure: improving acceptance and success of ... [https://bioelecmed.biomedcentral.com/articles/10.1186/s42234-025-00168-7]
• 45. How do you manage ANTICOagulant therapy in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7927258/]
• 46. Signal properties and stability of a chronically implanted ... [https://www.medrxiv.org/content/10.1101/2025.09.19.25335897v1.full-text]
• 47. Quantifying physical degradation alongside recording and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11419230/]
• 48. A method for efficient, rapid, and minimally invasive ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11838573/]
• 49. Quantifying physical degradation alongside recording and ... [https://pubmed.ncbi.nlm.nih.gov/40037510/]
• 50. Reducing equivalent magnetic noise by electrode design ... [https://www.sciencedirect.com/science/article/abs/pii/S0924424724008975]
• 51. Deciphering platinum dissolution in neural stimulation ... [https://www.sciencedirect.com/science/article/pii/S0142961224001091]
• 52. Nanoporous platinum microelectrode arrays for neuroscience ... [https://pubs.rsc.org/en/content/articlehtml/2025/ra/d4ra08957j]
• 53. Advances in bioelectronics for neural interfacing [https://link.springer.com/article/10.1557/s43579-025-00822-w]
• 54. ID: 336446 A Feasibility Study of an Endovascular Stent ... [https://www.sciencedirect.com/science/article/pii/S1094715924003106]
• 55. The endovascular treatment strategies of cerebrovascular ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11973697/]
• 56. Signal quality of simultaneously recorded endovascular , subdural and... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5976775/]
• 57. Overcoming failure: improving acceptance and success of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11907899/]
• 58. Silk-enabled conformal intraventricular interfaces for ... [https://www.nature.com/articles/s41467-025-64397-9]
• 59. The ultra-thin, minimally invasive surface electrode array ... [https://www.nature.com/articles/s41467-023-42860-9]
• 60. Long-term stability strategies of deep brain flexible neural ... [https://www.nature.com/articles/s41528-025-00410-x]
• 61. Invasive Brain–Computer Interface for Communication [https://www.mdpi.com/2076-3425/15/4/336]
• 62. Endovascular Neuromodulation: Safety Profile and Future ... [https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2020.00351/full]
• 63. The top BCI stories of 2025 so far [https://www.massdevice.com/top-bci-stories-2025-so-far/]
• 64. Material and design strategies for chronically-implantable ... [https://www.nature.com/articles/s41427-025-00613-8]
• 65. interfaces for minimally invasive Endocisternal stimulation and... neural [https://researchexperts.utmb.edu/en/publications/endocisternal-interfaces-for-minimally-invasive-neural-stimulatio/]
• 66. Silk-enabled conformal intraventricular ... | Nature Communications [https://www.nature.com/articles/s41467-025-64397-9?error=cookies_not_supported&code=c0a23400-8ce6-44c7-9eeb-956982615b28]
• 67. Stent-electrode recording array [https://en.wikipedia.org/wiki/Stent-electrode_recording_array]
• 68. A systematic review of endovascular stent-electrode arrays ... [https://pubmed.ncbi.nlm.nih.gov/32610291/]
• 69. A brain implant that could rival Neuralink's enters clinical ... [https://www.nature.com/articles/d41586-025-03849-0]